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From 1824 to Today

THOMAS JEFFERSON UNIVERSITY IS A UNIQUE INSTITUTION,
marked by dualities: simultaneously new and
deeply experienced; steeped in tradition and
heedless of traditional boundaries; professionally
focused and committed to knowledge-creation.
We conduct research both for itself and as an
essential part of the educational process. In
doing so, we fuse discovery, imagination and
application—weaving together the pursuit of
basic knowledge with its innovative translation
and creative application. We strive to redefine the
term “humanly possible” in disciplines ranging
from immunology and vaccine development
to design and creation of functional fabrics.
New to the ranks of Carnegie Research 2 Doctoral
Universities, Jefferson was born of two 19th
century academic institutions long respected for
education and research. We are committed to a
full spectrum of research; and we have created a
robust culture where impassioned faculty, students,
clinicians and technical staff collaborate across
the traditional divides between basic, translational,
clinical and applied. We honor both sides of
Abraham Flexner's assertion of the “usefulness of
useless knowledge” by pursuing knowledge for
its own sake and strategically mining practical
impact (and human benefit) from what we learn.
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Thomas Jefferson University traces its roots to
the 1824 founding of Jefferson Medical College.
A pioneer in medical education, it was the first
school where medical students learned by
observing experienced doctors treating patients
and, then, by participating in supervised, handson care. Since then, Jefferson researchers
have had a record of discovery and research
leadership in biomedical science and clinical
care; and the University’s research enterprise
now includes a health system with nearly four
million in- and out-patient visits a year.
In 2017, Jefferson joined with Philadelphia University
to form a globally engaged professional university.
Philadelphia University, founded in 1884, excelled
at training professionals for careers in textile and
material sciences, industrial design, architecture and
health professions. A leader in hands-on professional
education—exemplified by its pioneering “Nexus
LearningTM” model—it employed applied research
to connect students and faculty with public and
private organizations seeking solutions for practical,
real-world challenges. Today, companies, nonprofits
and government agencies—from Johnson &
Johnson and Federal-Mogul to NASA and Oak Ridge
National Laboratories—seek out the creativity and
expertise embodied in the research and education
programs that are Philadelphia University’s legacy.
On that substantial cornerstone, we are building an
even more robust research enterprise. We have, for
example, established a new seed-funding mechanism
(the Deans' Transformational Science Awards) and
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a bridge-funding program to address unanticipated
gaps in external grant support. We added staff to
reduce investigators’ administrative burden and
facilitate collaboration across research groups
and disciplines. And we launched new research
and development platforms such as the Jefferson
Institute for Bioprocessing (described on page 20).

Driving Forward, Strategically
If we are aggressive in building our research
capacities and platforms, we are highly disciplined
in our overall research strategy: identifying areas
of strength and meaningful opportunity, and
building programs that emphasize collaborative,
transdisciplinary and cross-professional
approaches. This strategy is most evident in
our Programmatic Research initiatives, which
aim to make rapid and meaningful advances
in understanding complex diseases and major
societal challenges. Programmatic initiatives
comprise teams of researchers with distinct,
complementary expertise, who pursue a cohesive
set of projects that often extends from basic
research to translational, clinical and applied.
In this report, we feature several of those
Programs—ranging from RNA Biology (page
38) and Fibrotic Diseases (page 46) to the
creation of 21st century smart cities (page 32).

The best current example of Programmatic
research’s ability to drive rapid and meaningful
advances is highlighted on page 18: our Vaccine
Center’s development of a COVID-19 vaccine
candidate (CORAVAXTM), which went into animal
trials in March 2020.
At the same time, Jefferson is dedicated to
supporting fundamental research on the most
basic questions of science, engineering and
society—studies driven not by institutional
strategy but by investigators’ passions to explore
very specific questions and follow the answers
wherever they lead. This report illustrates the
array of basic research studies we are pursuing—
on topics ranging from mitochondrial function
(page 56) to the epigenetics of lung disease (page
48) and the molecular basis of uveal melanoma
(page 11)—and it highlights how integral they are
to both the pursuit of new knowledge and the
discovery of solutions to specific challenges.
This report illustrates, too, the many ways that
Jefferson investigators are pioneering in the
application of new knowledge. From our clinical
research on reducing surgical infections (page 54)
and treating liver disease (page 42) to our applied
research and development projects—in fields such as
functional fabrics (page 50); medical and industrial

A NOTE ABOUT OUR RESEARCH CENTERS and INSTITUTES
One way we accomplish our distinctive
programmatic approach to research is by
organizing as multidisciplinary centers and
institutes around specific challenges. Led
by visionaries and staffed by experts, these
entities enable us to more quickly move
discovery to translation and application;
and they are excellent environments for
training colleagues and students to address
the practical challenges the world presents.
Many of the faculty members highlighted
in this publication are affiliated with one
or more of these research engines—
powerhouses of discovery such as:
• The NCI-designated Sidney Kimmel Cancer
Center at Thomas Jefferson University—
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which has been an international leader
in oncology research, patient treatment
and patient education for more than 25
years. The Center’s research program
includes cancer cell biology and signaling,
molecular biology and genetics—focusing
on a broad range of malignancies, including
prostate cancer, gastrointestinal cancer
and brain tumors.
• Vickie and Jack Farber Institute for
Neuroscience—where globally recognized
researchers and physicians from
neurosurgery, neurology, psychiatry and
neuroscience collaborate on advancements
in treating neurological injury and
neurodegenerative disorders, including

conditions such as Parkinson's disease,
epilepsy, ALS, MS, stroke, and spinal cord
and traumatic brain injury.
• Jane & Leonard Korman Respiratory
Institute–Jefferson Health and National
Jewish Health—where world-class
researchers pursue bold new avenues
of study on lung development and
respiratory diseases; focusing, for example,
on genetic determinants of airway
disease, pulmonary fibrosis, pulmonary
hypertension, lung inflammation and
tobacco-related disorders.



THE EPISTEMOLOGY of JEFFERSON RESEARCH
Research at Jefferson falls into three not-

This way of organizing knowledge follows the conceptual model

mutually-exclusive categories:

of scholarship presented in the 1990 Carnegie Foundation report
Scholarship Reconsidered. The model comprises three interacting

Basic/Discovery Research, which uncovers
fundamental new knowledge in the sciences,
engineering, social sciences and humanities.

types of scholarship that, together, define a flexible approach
that can apply to any discipline or professional field: Scholarship
of Discovery, the commitment to knowledge for its own sake;
Scholarship of Integration, which places special knowledge in a
larger context; and Scholarship of Application, where knowledge

Clinical/Translational Research, which tests
whether and how fundamental new knowledge
can be translated for use–for example, in the
clinical trial of a new drug.

is employed to address consequential human issues and often
engages external clients.
Virtually all of research at Jefferson—from Basic/Discovery to
Clinical/Translational to Applied—is grounded in or influenced
by all three Scholarship lenses. This works because of the

Applied Research, which subjects existing
knowledge to new processes and technologies,
and uses it to address specific needs for
individuals, communities or organizations. It is
the reduction-to-practice of prior research.

nature and range of professional and scholarly disciplines the
University encompasses, and because of its determination
to build transdisciplinary connections across the research
spectrum. As you read this report, you will note that each
article includes the appropriate category or categories to
identify where the subject falls in the epistemology.



use of hemp (page 14); and the design of lighting
for population health (page 28)—we are putting
new knowledge to use, expeditiously, efficiently
and productively to address real-world problems.
Overall, this document offers just a sample of the
exciting work we have undertaken in pursuit of
Jefferson’s research mission:

Advancing and applying
knowledge to improve

lives.

These pages reflect the tremendous level of
commitment, energy and momentum embodied
in the Jefferson research enterprise. And they
convey how proud—and ready—we are to join our
Carnegie Research 2 Doctoral University peers in
helping to define the future. 
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Mark L. Tykocinski, MD
Provost, Executive Vice President
for Academic Affairs, Thomas Jefferson University
The Anthony F. and Gertrude M. DePalma Dean
Sidney Kimmel Medical College
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BASIC// DISCOVERY + CLINICAL// TRANSLATIONAL

ADVANCING CELLULAR
and IMMUNE-BASED
CANCER THERAPIES

Scott Waldman, MD, PhD and
Adam Snook, PhD are developing a
vaccine to fight colorectal cancer.
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New Colorectal Cancer Vaccine

THE NCI-DESIGNATED SIDNEY KIMMEL CANCER CENTER (SKCC)
is the heart of Jefferson’s broad-based cancer
research program. SKCC investigators are
currently pursuing hundreds of basic science,
translational and clinical studies on cancer cell
biology and signaling, molecular biology and
genetics, and specific diseases ranging from
brain cancer to uveal melanoma. Among the
most exciting efforts are partnerships between
SKCC basic scientists and clinician-researchers
to both advance new immune-based therapies
and continuously improve current approaches.
Glioblastomas are aggressive brain tumors—and
very hard to eliminate completely. However, a
glioblastoma combination immunomodulatory
vaccine approach developed by Jefferson
researchers is now progressing into a phase II trial.
The immunomodulatory vaccine product is notable
for its initial success with a tumor type where
previous immunotherapy approaches have failed.
Created by David Andrews, MD, professor of
neurosurgery, and D. Craig Hooper, PhD, professor
of cancer biology, the vaccine employs a patient’s
own tumor cells collected during surgical removal
of the primary brain tumor. The researchers treat
those cells with an antisense oligodeoxynucleotide
(AS-ODN) containing immunostimulatory motifs.
The AS-ODN works against a receptor shown to
drive tumor growth and metastasis and the activity of
tumor-promoting, anti-inflammatory macrophages.
Next, the cells are loaded into a dime-sized
diffusion chamber with additional AS-ODN, and
the contents are irradiated. The chamber is then
implanted under the patient’s skin, allowing antigens
produced by the cells and the AS-ODN to diffuse
into the body to stimulate pro-inflammatory tumorimmune cells and boost anti-tumor immunity.
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A new Jefferson-developed colorectal cancer
vaccine also shows great promise. The adenovirus
vector vaccine works by prompting an immune
response specifically to a colorectal cancer tumor
antigen called guanylyl cyclase (GUCY2C), first
identified by Scott Waldman, MD, PhD, Samuel M.V.
Hamilton Professor of Medicine. Developed by Dr.
Waldman and Adam Snook, PhD, assistant professor
of pharmacology and experimental therapeutics,
the vaccine combines a GUCY2C molecule with
a molecule that boosts the anti-tumor activity of
CD8 positive cytolytic T lymphocytes. GUCY2C
is expressed by cells lining the intestine and by at
least several types of cancer cells; but, because
the vaccine is injected into arm muscle, it does not
come into contact with healthy intestinal cells.
In a phase I clinical trial, patients’ blood showed
markers of immune activation, suggesting that the
vaccine could train the immune system to attack
colon cancer cells that had spread before surgical
removal. In pre-clinical mouse studies, the vaccine
reduced the formation of colon cancer metastases
in the lungs by >99% percent and more than
doubled survival time. The researchers—who are
preparing for phase II trials of the vaccine—recently
found that GUCY2C is also expressed by gastric,
esophageal and pancreatic cancer cells. They will
pursue opportunities to test the vaccine with those
cancers as well.
GUCY2C is also the target of a new CAR-T-based
immunotherapy for colorectal cancer that Drs. Snook
and Waldman have developed. The therapy—which
engineers and re-infuses patients’ own immune
cells to target only the tumor—is preparing to enter
phase I trials. Previously, a human-ready version of
the therapy proved successful in killing tumors and
preventing metastatic growth in mice—more than
quintupling survival in cases with advanced lung
metastases. Notably, there were no off-target or
adverse effects of the treatment, which has been a
major problem for other CAR-T cancer therapies.
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Two-Step Approach
A unique approach to bone marrow transplant
(BMT) involving half-matched (haploidentical) donors
and higher-risk patients has proven as effective
as transplants that use traditional, fully-matched
donors. And continuing improvements in the
procedure are driving even better results for patients.
The “two-step approach”—developed by Neal
Flomenberg, MD, professor of medical oncology—
has been used in more than 300 procedures
involving half-matched donors since 2006.
Until recently, Jefferson was the only institution
in the nation using the two-step approach.

CLINICAL// TRANSLATIONAL

REAL WORLD DATA REVIEW
SHEDS LIGHT on MEDICAL
TREATMENT
In the largest population-based retrospective study

In traditional BMT, chemotherapy (and, sometimes, radiation therapy) is administered before
the patient receives an infusion containing both
T-cells and stem cells in a single step; then
immunosuppressive drugs are used to prevent
or limit the otherwise overwhelming immune
response that results in graft-versus-host disease
(GVHD). In the two-step approach, after half
the chemotherapy is administered, just donor
T-cells are infused; two days later, the remaining
chemotherapy is administered. (As a result, the
cells spurring GVHD are eliminated, which lessens
the need for a close HLA match.) Finally, an
infusion of highly purified stem cells is given.

on combination therapies for high-risk prostate

The two-step approach’s benefits for patients are
significant: less-aggressive regimes of immunesuppressant drugs; reduced incidence of GVHD;
and engraftment of donor cells that occurs more
quickly than with a traditional approach. Perhaps most
significantly, the process and time needed to find a
donor are reduced—a huge factor since approximately
only 30 percent of patients will have a family member
who is a full match. In addition, Dr. Flomenberg’s
approach gathers donor cells differently: rather
than extracting stem cells from bone marrow,
they are harvested from the donor’s blood. It is
less painful and less risky for donors, and enables
the physicians to better standardize the number
of cancer-fighting T-cells and stem cells (which
replenish depleted blood supply) given the patient. 

surveillance, screening and treatment for prostate

cancer, a team led by Grace Lu-Yao, PhD, MPH,
professor and vice chair of medical oncology,
found that more patients live longer if treated with
prostate removal (prostatectomy) plus radiation
therapy. The study was the first to show that
removing the whole prostate and following up
with radiation therapy is associated with greater
overall survival than simply treating the prostate
with radiation plus hormone-blocking therapy.
“Prostatectomy is an unpopular treatment,” notes
Dr. Lu-Yao, whose research findings on cancer
cancer provide critical data for treatment decisions
that improve patient care while reducing healthcare
costs. “Our study showed that only six percent of men
with high-risk cancer were treated with it. However,
we found that 10 years after treatment, 89 percent
of those who had prostate removal plus radiation
were still alive—compared with 74 percent of those
who received only radiation and hormone therapy.”
Yet there were trade-offs for the survival
advantages: Men who received prostatectomy
and radiotherapy had increased rates of erectile
dysfunction and notably higher rates of urinary
incontinence. “One of the strengths of population-

The glioblastoma and colorectal cancer vaccines reflect one
facet of Jefferson’s expansive basic science and translational
research on vaccines. See Vaccines Fighting Viruses and
Cancer on page 18 for a broader look at that work.
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based studies is that they reveal what happens in
the real world, rather than the carefully controlled
context of a clinical trial,” says Dr. Lu-Yao. 

Ten years after treatment,
89 percent of those who
had prostate removal plus
radiation were still alive.
Grace Lu-Yao, PhD, MPH
Professor and Vice Chair
of Medical Oncology
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Elda Grabocka, PhD
Assistant Professor of
Cancer Biology and Surgery

BASIC// DISCOVERY

HOW to RE-STRESS
PANCREATIC CANCER
WHAT IS THE MOLECULAR BASIS FOR PANCREATIC CANCER'S
aggressive nature and resistance to treatment?
Elda Grabocka, PhD, assistant professor of cancer
biology and surgery, is working to find out. Last
year, she received both a Margaret Q. Landenberger
Research Foundation grant—which supports
promising early-stage medical researchers—and her
first NIH/NCI R01 grant. She has also received a V
Foundation Scholar Research Award and a W.W.
Smith Charitable Foundation grant. Her research
investigates pancreatic cancer’s ability to hijack
the mechanisms by which normal cells adapt
stressors. Ratcheting up that mechanism allows
tumors to grow under adverse conditions and it
enhances their resistance to chemotherapy.
Ninety percent of pancreatic cancers are
associated with a mutation in the KRAS gene
(one of the category of genes that are associated
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with 30 percent of all cancers). Dr. Grabocka’s
lab has identified that mutant KRAS cancers
increase the activity of cell structures known
as stress granules, which has the effect of
enhancing tumor cell fitness and protecting it
from chemotherapeutic agents. Dr. Grabocka
and colleagues also developed methods that
enable researchers to more effectively determine
how stress granules are formed and how they
support the development of pancreatic tumors.
Building on these initial discoveries, Dr. Grabocka
is now using 3D cell culture models and mouse
models to study stress granules’ specific role in
drug resistance and to investigate how oncogenic
signaling and stress stimuli interact to promote
pancreatic tumor development. Ultimately, she aims
to develop strategies for targeting stress granules in
treatments for a range of RAS gene cancers. 

BASIC// DISCOVERY

CAN a PRIMROSE COMPOUND
FIGHT UVEAL MELANOMA?
Dr. Benovic and his colleagues recently identified
a compound derived from a type of primrose that
could be a potent inhibitor of metastatic growth in
uveal melanoma. It works by blocking a particular
UVEAL MELANOMA IS THE MOST COMMON EYE CANCER IN

type of G protein that sits on the cell membrane.

adults. It metastasizes to the liver in 50 percent of

In uveal melanoma, a subset of these G proteins

patients, and there are no effective therapies to

are mutated, turning on a molecular pathway that

treat those metastases. Yet.

leads the cell to become malignant. When Benovic

Jeffrey L. Benovic, PhD, Thomas Eakins Endowed
Professor of Biochemistry and Molecular Biology,
is globally recognized for research uncovering
the mechanisms of G protein-coupled receptor

lab researchers treated uveal melanoma cells
with small amounts of the compound, the cells
appeared to revert to their normal, non-malignant
state. And higher doses killed the cells outright.

(GPCR) signaling and how GPCR dysregulation

The next step: Dr. Benovic will work to confirm

contributes to disease. GPCRs regulate a variety

the findings in a mouse model of uveal

of biological functions—from neurotransmission

melanoma, collaborating with Takami Sato,

and sensory perception to the movement of

MD, PhD, K. Hasumi Endowed Professor of

cells in response to chemical stimuli. They

Medical Oncology, who directs Jefferson’s

have also been implicated in diseases ranging

Metastatic Uveal Melanoma Program—one of

from cancer to neurological disorders.

the nation’s only centers dedicated to both

GPCRs are the target of about 35 percent of

research and treatment of the disease. 

drugs currently on the market—including those to
treat cancer, cardiovascular and airway disease,
and neurological and metabolic disorders. Dr.
Benovic’s broad-ranging work on the regulation
of GPCR function is creating opportunities to
improve on those therapeutics. He is often a
catalyst for translational projects, collaborating
with clinician-researchers to create and test new
treatments for a variety of diseases.
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CLINICAL// TRANSLATIONAL

A NEW LOOK at CANCER
CARE DISPARITIES
THE DEATH RATE FROM CANCER IS NOTABLY HIGHER FOR AFRICAN
Americans than Caucasians, which derives from
disparities in screening, diagnosis, engagement in
clinical trials and therapeutic efficacy and less use of
hospice and palliative care among African Americans.
“The causes of these complex disparities reflect
social, cultural and economic inequalities more
than biological differences,” says Lisa WhitfieldHarris, PhD, MSN, MBA, assistant professor of
nursing. “Addressing them effectively will require
interventions that are developed in full partnership
with the African American community.”
She and two Jefferson colleagues—Clara GrandaCameron, DrNP, MSN, assistant professor of
nursing, and Jeannette Kates, PhD, CRNP,
assistant professor of nursing and director of the
adult-gerontology primary care nurse practitioner

12

THOMAS JE FFE RSON UNIVE RSIT Y // Jef ferson.edu/Research2020

program—are collaborating on two studies that
seek to clarify and begin addressing culturally
based reasons for cancer care disparities within
the African American population.

Promoting African American Engagement
in Clinical Trials
The first study seeks to address the fact that—
despite researchers’ increasing efforts over
the past 25 years—African Americans continue
to be underrepresented in clinical trials. This
underrepresentation means that trial results
often do not accurately gauge a treatment’s
effectiveness for African Americans.
“Through this project, called Empowerment
Through Engagement: African Americans as
Partners in Clinical Trials, we will develop a
culturally sensitive teaching tool to promote African

LEFT TO RIGHT: Yvonne Florence, Sisters R Us Circle of
Survivors; Jeannette Kates, PhD, CRNP; Clara GrandaCameron, DrNP, MSN; Lisa Whitfield-Harris, PhD, MSN, MBA

American community advocacy and engagement
in clinical trials,” says Dr. Granda-Cameron.
The study is a partnership between the Jefferson
researchers and the cancer survivors’ organization,
Sisters R Us Circle of Survivors. It will use a
community-based participatory research design
and Freire’s dialogue approach to explore
participants’ perceptions about participating
in clinical trials, as well as concepts of racism,
discrimination, resiliency and protective factors.
The results will then be employed as the basis for
collaborative development of the teaching tool.

Advance Care Planning among African
Americans Diagnosed with Cancer
The second project explores perceptions of advance
care planning among African Americans who have
been diagnosed with cancer. “There is consistent

evidence that African Americans are less likely to
engage in goals-of-care discussions, complete
advance directives or enroll in hospice or palliative
care,” says Dr. Kates.
Funded by a research grant from the provost’s
office, the project is using three structured
instruments and follow-up conversations to
measure and understand mistrust, decisional
control preference and advance care planning
readiness among study participants.
“Our goal is to use the information we gather
in this study to create a culturally sensitive and
highly effective intervention that helps increase
the number of African Americans who engage in
advance cancer care planning,” explains Dr. Kates. 
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APPLIED//

REDISCOVERING

HEMP:

New Materials, Manufactured Products
and Therapeutics

THROUGH MUCH OF RECORDED HISTORY, THE HEMP PLANT
was recognized as a sustainable, renewable resource
with myriad practical applications. Its fibers are strong,
resilient and possess unique chemical properties; its
seeds and leaves are nutritious; and parts of the plant
have medicinal benefits. However, for more than
50 years, its use in the United States was severely
restricted by policymakers who equated all hemp
products with just one: marijuana.
That situation has changed over the past decade.
Today, most restrictions on hemp have been lifted,
and states are legalizing marijuana and its byproducts for medicinal or recreational purposes.
That evolution has been driven by three factors:
growing consumer demand for products created
from renewable resources; better understanding of
the hemp plant’s complete physical and chemical
composition; and expanding awareness of the
known and potential medical uses of cannabinoids
(including the fact that the human body not only
uses cannabinoids but also manufactures its own).
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Ron Kander, PhD, and student Natalie Burgos
combine hemp hurd with biodegradable polymers
in a laboratory-scale ejection molding machine to
make hemp-reinforced polymer composites.
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Mark Sunderland '84, M'06, and Michael
Savarie '19 are evaluating material properties
of Nano-film made from hemp flower extract
to determine bio-test sequencing.

The basic and applied research associated with the
engineered industrial and consumer products of
the hemp initiative has been strategically guided
by Ronald Kander, PhD, Executive Dean of Kanbar
College of Design, Engineering and Commerce,
whose research focuses include composite
materials and sustainable manufacturing processes.
“Since 2017,” explains Dr. Kander, “Jefferson
researchers have been pursuing four integrated
goals: advancing basic scientific knowledge about
hemp and its components; exploring where
hemp could be a cheaper or more effective raw

material for existing products; conceiving and
creating wholly new biomedical and manufactured
products; and defining markets and sustainable
supply chains for those products.”
Toward those goals, Jefferson’s hemp-focused
research ranges from basic and translational science
and clinical trials to industry-sponsored ideation
and product development. It engages dozens of
departments across the University, from engineering
and textile design to chemistry and surgery. Here
we highlight two facets of the growing program.

Jefferson's hemp-focused research ranges from
basic and translational science and clinical trials to
industry-sponsored ideation and product development.
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Medicinal Cannabis

Manufactured Hemp
A collaborative research and development team—
including Dr. Kander; Mark Sunderland, MS,
Robert J. Reichlin High-Performance Apparel
Chair; Brian George, PhD, associate professor of
engineering and textile; and several colleagues—
have been exploring and applying many of hemp’s
absorptive, antimicrobial, electrical and mechanical
characteristics. The team’s efforts have led to
the development of a unique, environmentally
sustainable method for processing hemp—one that
creates new fibers and textiles using the whole
plant—that could soon be the basis for an array of
high-performance manufactured products with
unique characteristics. Those products could
include, for example, hospital gowns and working
surfaces that are resistant to staph infection and
the MRSA virus, and lighter, more durable yoga
mats and blocks. One line of products is now being
commercialized under the name Hemp Black.
Michael Leonard, MS Ed, MA Ed, Academic
Dean of the School of Design and Engineering,
is a scholar and practitioner of Industrial Design.
He and his colleagues are guiding a broad array
of student-driven research and development
projects focused on hemp. Some concentrate
on the development of consumer products,
such as kitchen surfacing that leverages hemp’s
antimicrobial qualities, dog-calming chew toys
made of CBD oil-infused hemp hurd (what
remains after the fibers are removed from a stalk)
or biodegradable 3D-printed seed starters. Dean
Leonard and his colleagues are collaborating with
a team led by non-woven materials expert Brian
George. But they also explore the other end of
the spectrum, asking questions such as, “Can we
design equipment that reduces the steps involved
in harvesting the plants and collecting their oils?”

Jefferson’s Lambert Center for the Study of
Medicinal Cannabis and Hemp is a nexus for crossdisciplinary, multicenter and multinational research
on the use of cannabinoid-based therapies. It also
provides evidence-based information on medical
uses of cannabinoid-based products to clinicians and
patients. The Lambert Center provided support to
Jefferson’s hemp initiatives and is currently supporting
several ongoing internal and external observational
and pre-clinical research projects. Future plans include
supporting more extensive research projects, with
several already under development.
The Lambert Center and the Institute for Emerging
Health Professions (IEHP, which is housed in the
Jefferson College of Health Professions) launched
three online graduate certificate programs in
Cannabis Medicine, Cannabinoid Pharmacology
and Cannabinoid Chemistry and Toxicology. IEHP
plans to develop one of the nation’s first master’s
degrees in medicinal cannabis. In addition, the
Center is working with researchers and clinicians
across Jefferson on research projects addressing
multiple areas, ranging from study design and
development of clinical data to the impact of
medicinal cannabis on key patient populations.
In parallel with those projects, the Department of
Rehabilitation Medicine is pursuing two current
studies. One project begins to address the dearth of
evidence on the long-term effects of marijuana use
by identifying health and functional variables that are
most (and least) influenced. It will monitor physical
health, cognitive function, quality of life and day-today function of three study groups: persons who
currently use cannabis, those who used it previously
but not currently, and those who never used it.
Beyond the basic knowledge it will produce, the
project will also provide a basis for outcome metrics
that can be applied to clinical trials on cannabisbased therapeutics.
The second project addresses patients’ perspectives,
experiences and knowledge of cannabis. Among
many uses, its findings will support development
of patient and caregiver educational programs that
counter broadly held inaccuracies. 
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VACCINES FIGHTING
VIRUSES & CANCER

Matthias Schnell, PhD, and his team
are developing vaccines to fight
diseases like Ebola, Lassa Fever
and COVID-19.
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A GROUP OF JEFFERSON VIRAL VACCINE RESEARCHERS LED
by Jefferson Vaccine Center (JVC) director
and professor of microbiology and immunology
Matthias Schnell, PhD have been using rabies
vaccine as a potent tool for understanding and
fighting hemorrhagic viruses—such as Ebola,
Marburg, Sudan and Lassa Feve—as well as
coronavirus. By the end of 2019, the team had
developed a tetravalent vaccine that uses an
established dead-virus rabies vaccine modified with
specific antigens for the viruses. In animal models,
the immune system develops a reaction to the
vaccine that is specific and can defend against
rabies and some viruses. Soon after COVID-19
first emerged, Schnell and his team created a
killed-rabies vaccine that incorporates the spike
portion of the SARS-COV-2 virus, which causes
the disease. The resulting COVID-19 vaccine
candidate—CORAVAX™—was put into animal trials
as a prelude to expected phase 1 clinical trials.

The importance of leveraging
our approach to create a

coronavirus vaccine
candidate is clear.
“Rabies is a prevalent problem in much of the
world, and it is extremely hard to prevent spread
of hemorrhagic viruses—evidenced by the most
recent Ebola outbreak. It would be valuable
to be able to provide immunity against these
diseases simultaneously,” Dr. Schnell says. "And
the importance of leveraging our approach to
create a coronavirus vaccine candidate is clear."
The NIH-funded project involves a bench-tobedside range of work: From identifying and
applying the antigens and observing the quality
of the antibody response to developing a
scalable production process to planning clinical
trials. With the vaccine having proved effective
and safe in small and large animal models, Dr.
Schnell’s team is working with a production
facility to ensure Good Manufacturing Processes
of the vaccine formulation. That process, which
should be completed in the coming year, will
be prelude to a subsequent phase I clinical
trial testing toxicity. If early clinical trials are
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successful, the vaccine could be ready to test
in actual disease outbreaks within five years.
JVC is the cornerstone of the University's
programmatic research in immunology and
infection disease. Building on basic and translational
studies in immunology, microbial pathogenesis
and tumor immunology, JVC researchers
pursue multifaceted investigations on vaccines
that combat viruses and those that provoke
immune response to diseases such as cancer.
JVC researchers are also seeing robust results
from their rabies-based vaccine for Nipah virus,
which is transmitted from animals to humans
and causes severe respiratory illness that can
progress into encephalitis, seizure and coma.
Outbreaks have occurred in Malaysia, Singapore,
Bangladesh and India; and because no vaccine is
available, the World Health Organization has listed
Nipah as needing urgent action. A recent study in
mice—testing a rabies vector that incorporates a
Nipah virus gene—showed that one dose of the
vaccine was safe and elicited strong antibodies
response against both Nipah and rabies. A
second, chemically killed version of the vaccine—
which could be ideal for immunocompromised
individuals—also safely induced strong immunity.
Rabies’ unique method for attacking the brain—it
bypasses the blood system and the blood-brain barrier
by entering the central nervous system (CNS) through
muscles at the site of an infecting bite—makes it a
perfect tool to learn about ways of harnessing the
power of the immune system to fight tumors in the
brain. Results from recent studies by JVC investigators
found that delivering rabies vaccine through a
mouse’s jaw muscles promoted an immune response
in the brain—one sufficient to prompt CNS immune
memory and protect against rabies in a way current
vaccines do not. The study also demonstrated
that for immune mechanisms to properly protect
the brain long-term, immune “memory” cells
must become resident in the CNS. That suggests
immunity established in the blood is insufficient to
fight brain cancer—a potentially pivotal finding for
development of vaccines against the disease.
That study was one in a series of projects in which
Jefferson researchers are translating their basic
science discoveries into immune-based cancer
treatments that have proven effective in early trials.
See Advancing Cellular and Immune-based Cancer
Therapies on page 6 for a look at that work. 
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JEFFERSON INSTITUTE for BIOPROCESSING:
Advancing Biologics R&D

A JIB employee sets up a 2 L bench scale
bioreactor for CHO cell culture.
BELOW: JIB is the kind of facility you see in
a manufacturing setting—and it is unique
among academic institutions.

JIB will help advance

research

and development of biologics,
supporting both academia
and industry.
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BIOLOGICS REPRESENT ABOUT 40 PERCENT OF DRUGS IN THE
therapeutics development pipeline, and currently
account for more than $200 billion in annual global
revenue. It is an area primed for extraordinary
growth. But research and development by
pharmaceutical companies and manufacturers—
and academic research centers—are limited by
the lack of trained professionals in this field.
To meet these critical workforce needs, Jefferson
established Jefferson Institute for Bioprocessing
(JIB). It is the first—and only—specialized education
and training institute for biopharmaceutical
processing in North America that combines
commercial single-use processing equipment with
a curriculum created in collaboration with the
Ireland-based National Institute for Bioprocessing
Research and Training (a joint effort of University
College Dublin, Trinity College Dublin, Dublin City
University and the Institute of Technology, Sligo).
JIB—which opened its 25,000 square foot training
and education facility in May 2019—provides training
to industry professionals through workshops and
certificate programs and hands-on education of

new bioprocessing engineers at the undergraduate
and graduate levels. “This is the kind of facility
you see in a manufacturing setting,” says Parviz
Shamlou, PhD, JIB’s executive director. “It is, we
believe, unique among academic institutions.”

Different Manufacturing Process
Means Challenges
The growth of biologics represents a major industry
shift from traditional chemical synthesis techniques.
Biologic pharmaceuticals are manufactured in a living
system, such as a microorganism, plant or animal
cell, often using recombinant DNA technology.
However, with a complex manufacturing process
and lengthier regulatory approval process compared
to traditional small-molecule drugs, biologics remain
challenging to produce.
“Biomanufacturing is going through an unprecedented
period of innovation in new products and growth in
legacy therapeutics,” says Dr. Shamlou. “JIB will help
advance research and development of biologics,
supporting both academia and industry.” 

CLINICAL// TRANSLATIONAL

PUBLIC HEALTH STUDY AIMS to
INCREASE HPV VACCINATIONS
Too often, cultural, educational and
demographic barriers hamper the public’s
use of vaccines. Among the most prominent
examples is the human papillomavirus vaccine
(HPV): roughly half of U.S. adolescents are not
vaccinated and remain vulnerable to the virus
and the cancers it causes.
“You’d have a hard time finding a parent
who doesn't want to protect their child from
cancer,” observes Amy Leader, DrPH, MPH,
associate professor of population science.
“Still, many parents are missing an opportunity
to protect their children from HPV, the most
common sexually transmitted infection and a
leading cause of cancers.”
Dr. Leader is deeply engaged in developing
and studying new approaches to increase HPV
vaccination rates among high-risk populations.
She and her colleagues recently completed an
NIH-funded study on strategies to increase HPV
vaccination rates among vulnerable populations
in the Philadelphia region.

The study had three aims. The first sought
to identify barriers to HPV vaccination in
Hispanic and African immigrant communities.
The researchers found that, despite a high
level of awareness of the HPV vaccine among
the broader Philadelphia-area population,
members of marginalized communities had
much lower awareness of the vaccine’s
availability and effectiveness, and received far
less information through media, community
and public health channels.
The second aim used citywide vaccination
records and data on social determinants of
health to identify novel predictors of HPV
vaccination; initial analyses suggest several
predictors, including neighborhood-level
economic stability.
The project’s final aim sought to better
understand the content and nature of public
discourse about HPV vaccination on social
media channels. The team found that antivaccine messaging was delivered most

often—and very effectively—through narrative
communication (in other words, storytelling).
In contrast, pro-vaccine messaging tended to
be built around objective data, which was less
compelling to many audiences.
“The data suggests that public health
messaging needs to be more engaging, more
focused on telling people’s stories than on
conveying nuts-and-bolts facts,” Leader
notes. To test that hypothesis, she and her
colleagues are undertaking an NIH-funded
randomized controlled trial that uses Twitter
to communicate either science-based content
or narrative messages that prompt feelings of
empathy, transportation, and identification.
Subsequently, they will then track the rates of
adolescent HPV vaccination.
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STEM CELLS as a
PATHWAY to NEURO
REGENERATION

BIOSCIENTISTS’ ABILITY TO CREATE INDUCED PLURIPOTENT
stem cells—which can be differentiated into many
kinds of cells has opened new pathways for
research and treatment of many medical conditions.
One of the most notable areas of advancement by
stem cell researchers at Jefferson is in treatment for
conditions affecting the central nervous system.
For more than 20 years, Lorraine Iacovitti, PhD,
professor of neuroscience, neurology and
neurological surgery, has been making major
research contributions in stem cell biology
and the use of induced pluripotent stem cells
(iPSCs) to pursue therapies for stroke and
neurodegenerative disease. Her breakthrough
discovery for prompting stem cells to differentiate
into dopamine neurons has overcome a major
obstacle to using iPSCs therapeutically. More
recently, in studying an animal model of stroke,
she discovered the existence of stem cell niches
in the brain, which means that new cells can be
created throughout the adult brain. That work also
showed a dramatic surge in stem cell proliferation
and differentiation due to molecular and cellular
changes in the blood-brain-barrier after stroke.
Her lab is now pursuing opportunities to leverage
these changes to deliver stem cell therapeutics.
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Recently, Dr. Iacovitti has also identified distinct roles
in Parkinson’s disease played by nervous system
cells called astrocytes. Parkinson’s is characterized
by degeneration of dopamine neurons in the
substantia nigra region of the brain, while those of
the neighboring ventral tegmental area (VTA) are
relatively spared. In comparing the two regions,
Dr. Iacovitti found that astrocytes in the VTA
produce growth factor GDF-15, which can protect
dopamine neurons from the disease. The findings
suggest that microenvironments in the brain may
play a significant role in neurons’ susceptibility to
neurodegenerative disease—and they raise the
tantalizing possibility of a new Parkinson’s therapy
using patient-specific iPSC-derived VTA astrocytes.
Iacovitti’s colleague, Angelo Lepore, PhD, associate
professor of neuroscience, is also using iPSC-derived
astrocytes, but for a different purpose: to study
cellular mechanisms underlying traumatic spinal
cord injury (SCI). He is particularly interested in
understanding SCI-related respiratory dysfunction and
chronic neuropathic pain; and he hopes to develop
stem cell-based therapies that both address the
primary injury and protect neurons during the period
of secondary damage that patients experience.
Toward that end, Dr. Lepore is working on several
research paths involving astrocytes: identifying
molecules that inhibit or promote regeneration of
the axons that extend from nerve cells; uncover
astrocytes’ role in maintaining normal nervous system
function; and to pinpoint how alterations in synapse
signaling contribute to SCI disease processes.
It is known that, after SCI, astrocytes often lose the
capacity to properly regulate glutamate in neuronal
synapses, which contributes to further neurological
damage. Dr. Lepore’s lab has demonstrated that

Lorraine Iacovitti, PhD
Professor of Neuroscience,
Neurology and Neurological Surgery
Angelo Lepore, PhD
Associate Professor of Neuroscience

transplanting iPSC-derived astrocyte progenitor
cells can help protect respiratory function in animal
models of SCI. Now they are doing the fundamental
work necessary to demonstrate the potential of using
patient-specific iPSC-derived astrocyte progenitor
cells therapeutically.
Astrocytes also naturally promote growth of axons,
which are long fibers that extend from neurons
to convey electrical signals to other neurons and
muscles—a significant fact, given that axons do
not regenerate after central nervous system injury.
Dr. Lepore and his colleagues are engaged in a
long-term NIH-funded study of the role astrocytes
might play in promoting of axon regeneration
and sprouting to recovery of respiratory function

following SCI. Thus far, using a rat model of SCI,
the researchers have demonstrated that astrocyte
stem cells transplanted at spinal injury sites promote
robust axon growth and significant restoration of
diaphragm function—by prompting regenerating
axons to reconnect the neural circuit between brain,
spine and diaphragm that regulates breathing. They
have also found that astrocytes significantly dampen
the pro-inflammatory response that promotes
secondary damage. In their continuing work, they
are selectively silencing defined neuronal populations
involved in respiratory control, in order to understand
which kinds of axon growth actually promote
recovery of diaphragm function—information that
will be essential to develop new therapies. 
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TEAMING UP on AUTISM
AUTISM SPECTRUM DISORDER (ASD)—THE MOST COMMON
neurodevelopment disorder of childhood—
is characterized by challenges with social skills
and communication, repetitive behaviors and
sensory sensitivities.
The Jefferson Autism Research Program is
comprised of a team investigating the molecular,
genetic, synaptic and functional aspects of ASD.
Program researchers and clinicians translate newly
gained knowledge into treatments and behavioral
interventions intended to improve the function and
quality of life of those with ASD.
Roseann Schaaf, PhD, professor of occupational
therapy, leads a multi-project study investigating
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ASD-associated sensory perception and integration
difficulties. These often include hypersensitivity to
sounds, sights and tactile sensations and trouble
perceiving and integrating those sensory inputs—
and can lead individuals with ASD to become
overwhelmed and unresponsive. In addition, she
is investigating whether occupational therapy
designed to address ASD-related sensory challenges
can create long-lasting improvements in everyday
functional skills. Dr. Schaaf’s lab is conducting a
large, NIH-funded clinical trial of sensory integration
interventions in collaboration with Albert Einstein
Medical Center in New York. The project tracks both
improvements in children’s functional capacities
and changes in their brains’ neurological processing.

LEFT TO RIGHT: Matthew Dalva, PhD;
Diane Merry, PhD; Roseann Schaaf, PhD;
Judith Ross, MD

And she is developing and testing an assessment
of sensory features in ASD, which should allow for
more precise identification and treatment of an
individual’s sensory challenges.

CLINICAL// TRANSLATIONAL

ASD is more prevalent in males, but the reason is not
clear. Diane Merry, PhD, professor of biochemistry
and molecular biology, is working toward an answer
by studying the basic biology of two proteins
produced by sex-chromosome-linked genes. These
proteins, which are critical to synapse formation
and stabilization, have increased expression in boys
with some types of ASD. For these studies, Dr. Merry
is creating specialized lines of patient-derived stem
cells, which can be turned into neurons in order to
study the biochemical and functional characteristics
of these synaptic proteins.

Creativity is an increasingly important skill for navigating the
21st century. But how do human beings acquire that skill?
Can it be taught? Richard W. Hass, PhD, assistant professor
of psychology, believes it can. “I want to understand the
processes through which we solve problems creatively,” he
says, “and then use those processes as the basis for curricula
that prepare students to hone creativity as a tool for managing
life in a swiftly changing economy, society and environment.”

Mounting evidence indicates that ASD is a
“synaptopathy”—a disease rooted in atypical
function of the synapses through which brain
neurons communicate. Matthew Dalva, PhD,
professor of neuroscience, directs the Jefferson
Synaptic Biology Center (SBC), which seeks to
address how these building blocks of the brain
form, function and are linked to disease. His
laboratory uses leading-edge imaging and new
molecular tools to study how synapses are made
and lost, and what impact abnormal morphology
and quantity of synapses have on brain function.
Dr. Dalva’s current studies address synaptic
defects in ASD, but his work—and that of his SBC
colleagues—will likely also shed light on a range of
other neurological conditions including addiction,
Alzheimer’s and neurodegenerative disease.
Judith Ross, MD, professor of pediatrics, directs
the Extraordinary Kids Clinic at Nemours/Alfred
I. duPont Hospital for Children, which serves
children with X and Y chromosome variations.
She has more than 25 years of NIH-funded
pediatric research experience focused on
neurodevelopmental outcomes in children with
X and Y chromosomal disorders such as XYY,
Klinefelter and Turner syndromes. Her Jefferson
lab applies that basic science expertise and her
deep clinical experience to the challenge of
uncovering ASD’s genetic roots. 

CAN WE TEACH CREATIVITY?

Toward that ambitious goal, Dr. Hass is pursuing a broad range
of interdisciplinary studies on the cognitive and social processes
underlying creative thinking, conceptual combination and
motivation. His collaborators include experts in philosophy,
neuroscientists, anthropologists, statisticians and experts
in educational assessment—from institutions around the
globe, including University of Alberta, Canada, and The Free
University of Berlin, Germany. Their projects include:
• studies on how memory search processes enable people
to generate novel ideas;
• an investigation of the interplay of cognitive and motivational
variables in predicting real-world creative achievement;
• the identification of common facets of human idea-generation
and problem-solving processes—and comparison of those
facets with artificial intelligence strategies;
• development of creativity measurement tools and assessments
of how feedback affects the problem-solving process.

Applying Research to Curriculum Development
As the research produces concrete findings, Dr. Hass is applying
them to curriculum development and to assessments of the
classroom experience. With Jefferson colleagues, he is:
• helping to develop and pilot a creativity core curriculum for
use across the university studying the correlation between
teachers’ beliefs about creativity generally and about teaching
for creativity;
• working with the Jefferson Center for Interprofessional Practice
and Education to perform statistical analysis on—and create
outcomes-based assessments of—team-focused education.
“The curriculum we are developing will, we believe, help our
graduates to creatively—and successfully—address challenges
and tasks for which there is no single ‘right’ answer,” Dr. Hass
explains, “and to use what they know to confront situations
involving outcomes that may be inherently unknowable.”
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INCREASED ACTIVITY MAY
PREVENT COGNITIVE DECLINE

Participating in cognition-enhancing
activities might reduce African
Americans' risk for dementia.

AFRICAN AMERICANS ARE AT NEARLY TWICE THE RISK AS
Caucasians for developing Alzheimer’s and other
dementias. Yet, no interventions have been shown
to reduce this disparity.
Barry Rovner, MD, professor of psychiatry,
neurology and ophthalmology, and a clinical
expert in Alzheimer’s disease, has been intensely
studying racial-based disparities in the incidence
and outcomes of dementia. In one notable study,
he and Robin Casten, PhD, professor of psychiatry,
found that African Americans were less likely than
whites to recognize cognitive decline as a medical
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problem. Those findings suggested that culturally
specific interventions might help reduce African
Americans’ risk for developing dementia.
Therefore, Drs. Rovner and Casten undertook an
NIH-funded trial of a behavioral intervention that
increased participation in cognitive, physical and
social activities among African Americans with mild
cognitive impairment, a transition state between
expected cognitive aging and dementia. In the
intervention, community health workers used
goal setting and action planning to guide at-risk
participants in concrete steps to increase cognition-

enhancing activities. In results published last year,
the research team reported that the intervention had
clear benefit in helping prevent memory decline in
this high-risk population. The behavioral intervention
reduced risk of cognitive decline by 88 percent,
compared to a control group.
Dr. Rovner attributes much of the intervention’s
success to the study’s sensitivity to the perceptions
of the African American participants. The
community health workers were themselves
African American, and the participants were able
to self-select the specific activities they pursued—
which included relearning chess, playing guitar,
rejoining a church group, making plans to meet
friends for lunch and walking to appointments.

microvascular disease and neurodegeneration and,
thereby, increase risk for dementia. The number of
older African Americans with diabetes in the U.S. will
double by 2030, and African Americans have worse
glycemic control than Caucasians.
To address these disparities—and the related
incidence of dementia—Drs. Rovner and Casten are
planning a clinical trial on the Efficacy of DiabetesSpecific Behavioral Activation. The researchers
hope that, by reinforcing diabetes self-care and
addressing African Americans’ negative beliefs about
medications and physicians, the intervention will
simultaneously improve diabetes care and prevent
dementia in this high-risk population. 

While conducting the study, the researchers
became more aware of the problems facing
African Americans with diabetes—which can cause

BASIC// DISCOVERY

EXCITING FINDINGS on EPILEPSY
Epilepsy, one of the most common
neurological conditions, is characterized
by recurrent seizures prompted by
abnormal, excessively synchronous firing
of neurons in the brain. It may be caused
by abnormal brain connections, an
imbalance of neurotransmitters or changes
in signaling channels within brain cells.
For about 70 percent of patients, seizures
can be controlled with pharmaceutical
treatments. But for many—especially those
who experience prolonged seizures—
current treatments are ineffective and
epilepsy can be life-threatening.
Clinician-scientist Michael Sperling, MD,
Baldwin Keyes Professor of Neurology, is
internationally known for his work in epilepsy
surgery and electrophysiology. He integrates
clinical practice with research, trying to
understand why certain patients benefit from
available treatments—and to identify new,
effective therapies for those who do not. Dr.

Sperling founded and directs the
Jefferson Comprehensive Epilepsy Center,
noted for its basic science and clinical
research on epilepsy’s underlying mechanisms
and on experimental therapeutics. Center
researchers are using electrophysiology,
structural MRI and functional MRI to map
seizure spread within the brain, observe
seizure effects on structures involved in
cognition, memory and language and develop
methods for preventing seizure onset.
Recently, Center researchers found that some
seizures start after a burst from neurons that
inhibit brain activity. In other words, neurons
that dampen other neuronal activity may be key
to starting the large-scale hypersynchrony that
becomes a seizure. The study, which was part
of the group’s search for activation-and-resting
patterns that correlate with more significant
seizures, was the first time that the preseizure neural inhibition was seen in patients.
In the study, performed in collaboration with

neurosurgeons at Jefferson and University of
California at Los Angeles, patients undergoing
preparation for epilepsy surgery had electrodes
placed in the brain to determine the exact
location of seizure onset. The electrodes then
captured signals from the individual excitatory
and inhibitory neurons involved in the seizures.
Analysis of cell signaling showed that inhibitory
neurons fired immediately prior to the excessive
discharge of excitatory neurons. This inhibitory
burst may increase the likelihood of subsequent
hypersynchronous firing that leads to a seizure.
Among the researchers’ goals in leveraging
these findings is to develop a way to use the
pre-inhibition phenomenon as a biomarker
for determining who will (and will not)
respond to seizure-prevention therapy. Other
biomarkers are also being investigated—
in particular, functional MRI signals—in
hopes of better predicting response to
therapy and developing new methods of
modifying abnormal neuronal firing.
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LIGHT4HEALTH:
How Does Light Impact Health?

WE USE LIGHT TO CONTROL HOW WE PERCEIVE AND ENGAGE
with environments in which we live, work and play.
In turn, light affects our endocrine system and
circadian rhythm and impacts our emotions, focus
and performance. And the practical purposes to
which we apply light are expanding dramatically.
Light Research at Jefferson addresses a wide
spectrum of questions on how we do—and could—
use light, and how light affects human psychology
and physiology. It includes both deep, fieldspecific investigations and interdisciplinary work
engaging faculty from architecture and interior
design to engineering and material science to basic

Light4Health’s researchers and design practitioners

bioscience and clinical care.

are developing a transdisciplinary curriculum

It also extends to education: Jefferson is a
key partner in Light4Health, an international
collaboration to develop an innovative health
research-based academic curriculum in lighting
design education. The project is underwritten by
Erasmus+, the European Union’s program that
promotes infusion of research-based discovery
back into education to address emerging societal
needs. Jefferson’s collaborators include universities
in Denmark, England, Germany, Russia and Sweden.

on the intersection of lighting design and health
research—integrating methods and tools from
neurology, photobiology and neuroendocrinology,
and findings from research in neurobehavior,
psychophysiology of perception and behavioral,
cognitive and environmental psychology.
Lyn Godley, associate professor of industrial
design, is the project’s principal investigator at
Jefferson. She brings to bear both substantial
design expertise and a talent for nurturing young
designers—as well as a track record of developing
innovative, cross-disciplinary curricula that link
multiple design fields with business, engineering
and science. Godley’s key partner on the project
is George Brainard, PhD, professor of neurology
and widely respected director of Jefferson's
Light Research Program—which, among its many
projects, is working with NASA to develop and
test lighting solutions to the disruption of sleep
and circadian rhythms that astronauts experience
during space flight. 
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Rowena McBeath, MD, PhD
Assistant Professor of
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A KEY to PREVENTING
TENDINOSIS
RESEARCHERS HAVE LONG KNOWN THAT WITH AGE, BLOOD
supply to tendon cells decreases, leaving them
starved of oxygen. But knowing why this occurs
and why it causes tendons to fray with age can
be critically important to creating treatments that
eliminate the need for surgery for tendinosis, a
painful orthopedic condition.
An intriguing NIH GEMSSTAR-funded study by
Rowena McBeath, MD, PhD, assistant professor of
orthopedic surgery, found that the paired reduction
of oxygen supply and the signaling molecule Rac1
causes aged tendon cells to change shape and
flexibility. The findings have broad implications
for both injury prevention and tissue repair.
In Dr. McBeath’s study, donated human tendon
cells were grown in an environment mimicking
the low-oxygen environment common in older
people. Those cells changed shape and became
round and more similar to tough cartilage-like
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cells; in addition, older tendon cells reduced their
production of the signaling molecule Rac1, which
helps govern cell shape movement, and growth.
With reduced Rac1, the tendon cells began to
change shape—but only in low-oxygen conditions.
Now, Dr. McBeath is exploring whether increased
Rac1 production might enable tendon cells to keep
their shape and thus prevent tendinosis and the
associated pain. She and her team are also working
in the opposite direction: studying the possibility
of using decreased levels of oxygen and Rac1 to
spur cells to become fibrocartilage. Success in that
effort could ultimately give clinicians the ability to
grow patient-specific tissues to replace damaged
tissue in the knee, hip or spine—in the long term,
potentially obviating the need for joint replacement
surgery. Dr. McBeath’s new work has also received
NIH support through a five-year K76 Beeson Career
Development Award. 
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IDENTIFYING BIOMARKERS
to ASSESS PEDIATRIC
SPINAL INJURY
DIAGNOSING AND ASSESSING SPINAL CORD INJURY (SCI)
in children and adolescents has long been a
challenging task, as has been the application of
relevant and established outcomes measures
for these patients. “In adults, the neurological
consequence of SCI is determined by physically
examining 56 sites on the patient’s body—
examinations that require full participation and
cognitive awareness,” explains Mary Jane (MJ)
Mulcahey, PhD, professor of occupational therapy.
“But we showed in a study of 236 children with SCI
that children younger than six years—and some
up to 10 years old—are not able to participate
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effectively. The clinical assessment of SCI is also
challenging with adults who have brain injury or are
in a coma or medical-induced sedation. We need to
develop imaging biomarkers that tell us—regardless
of a patient’s age or mental capacity—the precise
extent of damage.”
With a team of biostatisticians, engineers, neuroradiologists, neuroscientists, occupational therapists
and physicists, Dr. Mulcahey has been developing
and validating spinal cord imaging biomarkers
and testing the feasibility of neuroimaging to
predict SCI outcomes. Their proof-of-concept
study employed diffusion tensor imaging (DTI) to

BASIC// DISCOVERY

COUNTERING SPINAL DISC
DEGENERATION

MJ Mulcahey, PhD, met Miki Greenstein, pictured, soon after
he had a spinal cord injury at the age of 13. She has worked
with him for 20 years now, and he is a frequent participant
in her research studies. Here, she and student Samantha
Burke work with Miki on a SaeboReJoyce rehabilitation
workstation that helps with arm and hand training.

This work could fill a major
gap in pediatric care.
Mary Jane Mulcahey, PhD
Professor of Occupational Therapy

effectively analyze both direct and indirect spinal
cord damage in children and youth between
birth and 21 years old at the time of injury.
Since then, funded by the NIH, the team has
successfully employed an expanding array of
imaging technologies to visualize in detail the
original injury and subsequent pathologies.
Those techniques have included the spinal
cord cross-sectional area, which offers a
structural biomarker for spinal cord atrophy
and related pathology; and fiber tractography,
which provides a 3D reconstruction of
neural tracts using data collected by DTI.
Throughout the studies, the researchers have
correlated biomarker-focused discoveries and
observations of patients’ clinical presentation.
Now, they are ready to take the important next
step: developing and testing projections for
individual patients, based on comprehensive
imaging studies of newly injured patients
and multi-year tracking of their progress.

The pain caused by spinal disc degeneration affects
millions of people worldwide and, too often, causes
disability and opioid addiction. Current therapies for
degenerative disc disease address only symptomatic
relief. However, it may be possible to address the
underlying problem by using endogenous stem
cells to rebuild diseased or degenerated tissues.
Longtime research collaborators Makarand Risbud,
PhD, James J. Maguire Professor of Orthopaedic
Surgery, and Irving Shapiro, PhD, Gertrude and
Anthony DePalma Professor of Orthopaedic Surgery,
are working to understand the cellular mechanisms
underlying disc degeneration, identify conditions
that enhance disc cell survival and create tissueengineering methods to regenerate healthy discs.
They are characterizing disc progenitor cells from
both normal and diseased discs; then defining
environmental conditions that enhance progenitor cell
differentiation into cells that comprise the disc’s inner
tissue, the nucleus pulposus. Drs. Risbud and Shapiro
hypothesized that adult mesenchymal stem cells (MSC)
transplanted into the disc will assume nucleus pulposuslike characteristics and help restore degenerated disc
tissue—and, thus far, they have shown that MSCs
differentiate into nucleus pulposus-like cells under
conditions similar to those existing in the disc in vivo.
On a parallel track, Drs. Risbud and Shapiro are
characterizing a mouse model of spontaneous, early
onset disc degeneration. (The lack of appropriate
small-animal models has impeded research on the
mechanisms underlying and driving the early onset
process.) These models will also be important for
testing the efficacy of the MSC-derived tissues. To date,
the researchers have demonstrated that their mouse
model recapitulates many features of human disc
degeneration, including compromised cell survival and
the changes to the cellular environment that lead to
compromised tissue function. In addition, compared to
control animals, the mouse model discs were stiffer, had
decreased height and poor vertebral bone quality.



“To our knowledge, we are the only group seeking
to define and validate pediatric SCI imaging
biomarkers,” Dr. Mulcahey observes. “We are
excited about this work because it could fill a
major gap in pediatric care—and, potentially,
inform better treatment of adult SCI too.” 
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Architecture students designed a 3D
model of Philadelphia in the year 2050 as
part of Professor Edgar Stach's Highrise
Buildings class on Smart Cities.
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BUILDING BETTER

CITIES

CONTEMPORARY CITIES ARE, SIMULTANEOUSLY, ECONOMIC
powerhouses and wells of extreme poverty;
catalysts of efficiency and prodigious consumers
of energy; places with excellent health care and
unhealthy air. To a significant degree, the future of
human society depends on our ability to resolve
these contradictions by making cities “smarter”—
i.e., healthier and more efficient, sustainable,
economically productive and equitable."
Jefferson is applying its deep expertise in
architecture, design, planning, material science and
public health to a growing, multifaceted program of
research on how to create (and recreate) cities as
society needs them to be. Here are snapshots of how
three faculty members are working toward that goal.

A Place for Addressing IDEAs
Kihong Ku, DDes, associate professor of architecture
and Volpe Family Term Chair for Architectural
Innovation, researches new technologies for
addressing architectural design challenges, such as
enhancing construction safety and developing new,
sustainably created and energy-efficient building
materials. He also works to improve the processes
that underpin the conception and development of
new products and solutions.
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“There are tremendous opportunities for research
and innovation in the building design process, and
in how new construction materials are developed,
and for meaningful cross-disciplinary collaboration
in applying new technology to realize those
opportunities,” says Dr. Ku.
At Jefferson, architectural knowledge, expertise,
creativity and advanced technical resources are
fruitfully combined in the Interdisciplinary Design
and Experimental Architecture (IDEA) Studio,
which Dr. Ku founded and directs. The IDEA Studio
is an innovative applied research framework for
engaging and educating upper-level architecture
students in cross-disciplinary design research that
bears on open-ended questions.
In the IDEA Studio, faculty, outside practitioners
and students from the fields of architecture, textile
design, engineering, industrial design, medicine
and others address various subjects. These include
creation of novel 3D structures with textiles or
textile-creation methods like knitting, and the
use of such materials and methods to design
and prototype adaptive building envelopes as
a sustainable energy strategy. Underlying this
approach is computational design thinking and
technologies that enable teams of collaborators
to analyze large amounts of data from multiple
perspectives and to evaluate how building
systems work, individually and in combination.
Studio participants learn from various sources,
including computational and systems biologists
who explore complex human biological processes
through parametric and system modeling. The
design of adaptive building envelopes can take
advantage of similar approaches which adapt
a material’s intrinsic physical properties to
create components and systems that react to
environmental forces in a different manner.
“We can use evolutionary algorithms to simulate
real performance and quickly run multiple iterations
that model an array of scenarios to produce brilliant
and unexpected solutions to architectural problems
once thought intractable,” notes Dr. Ku.
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The

future of human society

depends on our ability to
make cities "smarter."

Focusing on South Africa
For more than a decade, Christopher Harnish,
MArch, associate professor of architecture, has
focused his research and practice on resilient
humanitarian architecture in South Africa which is
the world’s most quickly urbanizing area. Through
the exploration and use of participatory design
methodologies and high-performance/low-tech
environmental strategies, Harnish has designed
community, education and arts facilities in South
Africa and Malawi. In addition, while serving as a
Fulbright Teaching Scholar Fellow at the University
of Malawi Polytechnic—where he guided Malawian
architecture students in using design to advance
equity, sustainability and resilience—he created a
research-based design for the Malamulo Mission
Hospital and its 80-acre hospital campus.
“Much of architectural research consists of highperformance, high-cost building assemblies—
exceptional examples that serve narrow interests,”
says Harnish. “More important to me is exploring
design processes and products that meet real needs
of a broad swath of the population. This is especially
important in the global South, where what is
‘exceptional’ is often impractical and unsustainable.”
For that reason, Harnish is pursuing research
projects that go well beyond traditional
architecture and design topics—for example,
collaborations on quantitative medical and public
health research that will inform new healthcare
facilities in South Africa. He is currently developing
a collaborative research project in Malawi to
improve the design of public health centers using
evidence-based, quality-of-medical-care research.
Those projects include analysis of facilities, needed
to enable pregnant women to move closer to a
distant hospital two weeks before their due dates,
so that delivery care is immediately available; and
spatial studies necessary to design hospitals that

enable small medical staffs and limited technical
facilities to most efficiently and effectively serve
a large number of patients.
The approaches that Harnish is bringing to
architecture projects in the cities of South Africa
have the potential to enhance the value and impact
of community-focused architecture in regions
throughout the world.

Concern for the Built Environment
Edgar Stach, Dipl.-Ing., professor of architecture,
is a practicing architect and an internationally
respected leader in research and design of
smart cities, high-performance buildings and
renewable energy technologies. His work focuses
on energy efficiency, ecological sensitivity and
responsibility, and reflects his concern for the
built environment. He has received national and
international design awards and recognition
for his accomplishments in these areas.

Stach’s current research centers on innovative
techniques and advanced technologies for energyefficient architecture. He serves as a joint faculty
member at Oak Ridge National Laboratory’s
Building Technologies Research and Integration
Center. Previously, he was a member of the faculty
at University of Tennessee, where he founded
multidisciplinary research platforms for highperformance buildings, sustainable architecture
and solar energy harvesting. His ongoing focus on
materials, technology and sustainability is supported
through a mode of working that combines
practice, teaching and research, as well as active
engagement in the discourse of contemporary
architecture through international design
competitions and collaborations.
Stach has published more than 50 scientific papers
and technical publications, and a scholarly book
on architect Mies van der Rohe. He is currently
writing a volume on Renzo Piano. The combination
of knowledge, ideas, experience and skills that he
brings to his research and his teaching are catalyzing
today the conception and development of buildings
that will comprise the cities of tomorrow. 

Chris Harnish and biomedical
engineering students from the Malawi
University of Science and Technology
captured drone footage that Jefferson
students use to help redesign Malawi's
Kamuzu Central Hospital.
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LANDSCAPE ARCHITECT as
COMMUNITY TRANSFORMER

“ONE OF THE HALLMARKS OF CITIES WITH HIGH POVERTY RATES
like Philadelphia is that children are profoundly
disconnected from nature,” notes Kimberlee Douglas,
MLandArch, associate professor of landscape
architecture and Anton Germishuizen Stantec Term
Chair in Landscape Architecture. “My colleagues and
I are investigating ways to recreate that connection
and then observe the effects on health, community
engagement and other key metrics.”
Douglas believes that each landscape project
must consider natural systems as well as social,
historic and economic frameworks. This approach
has driven her award-winning designs for projects
such as the Cynwyd Heritage Trail—a rehabilitated
brownfield rail corridor in Bala Cynwyd, PA—and
the innovative, sustainable Linwood Avenue
Neighborhood Park, in Ardmore, PA. It is also
central to her applied research on ecological
revitalization of urban neighborhoods and the
benefits of nature for children in cities.
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Developing “Green Networks”
Her current project is testing the development of
“green networks,” a series of small neighborhood
nature parks that harness a hidden asset in many
low-income neighborhoods—vacant lots. The
project’s ultimate objective is two-fold: enable
every child to live within a 30-second walk of a
green space; and create a verdant necklace running
throughout the city’s most economically depressed
communities. Combining education and community
engagement with research, Douglas employs
local students to develop and use survey tools to
observe and record characteristics of community
strength and weakness and to photograph and
map physical changes in the neighborhood.

Kimberlee Douglass, MLandArch, works
with community members to set up
small parks as part of a "green network"
in Philadelphia.

“Philadelphia has roughly 40,000 parcels of
open space,” Douglas says. “They represent
40,000 chances to build safe green places, raise
neighborhood property values and improve the
health of children and adults alike.” These parcels—
and Douglas’s initiative—also represent a model
that can be adopted by cities across the country
and around the globe.
Many of her colleagues agree: In 2019, Douglas
earned the American Society of Landscape
Architects’ Community Service Award. “Her
enduring and sustained community service has
made a lasting impact on many neighborhoods
in Philadelphia in providing quality green spaces
in low-income neighborhoods,” says Barbara
Klinkhammer, Dipl.-Ing., executive dean of the
College of Architecture and the Built Environment.
“She serves as an enthusiastic ambassador of the
power of landscape architecture in transforming
the urban environment.” 

BASIC// DISCOVERY

A CAREER ADVANCING MIDWIFERY
The year 2019 was a significant one—even
for a clinician-researcher as accomplished
as Barbara Hackley, PhD, CNM, associate
professor of midwifery and women’s health
and the Dorothea Lang Term Chair. Prior to
joining Jefferson in 2017 to launch and direct
the Jefferson Doctor of Midwifery Program—
the nation’s first discipline-specific doctoral
program for midwifery—Dr. Hackley served
on the faculties of Georgetown, Columbia
and Yale universities. And, during a career
that has, thus far, spanned three decades, she
received countless awards for her teaching
and research—and for her clinical expertise in
expanding mental health care, immunization,
asthma care and obesity management services
to pregnant and postpartum women.
Still, 2019 was special. Early in the year, Dr.
Hackley and colleagues published the results

of two important research studies. The
first explored the impact of a community
health center-based initiative to assist
families in accessing New York City’s prekindergarten program—finding that it resulted
in substantially higher numbers of African
American and Latinx families applying for and
enrolling in the pre-K program. The second
study, of group prenatal and well-baby care
efforts, documented for the first time that
those clinical interventions are associated
with long-term benefits that persisted for two
or more years. This study also revealed that
perinatal group care was beneficial in areas
not yet reported in the literature: nutrition,
family communication and parenting.

Lifetime Achievement Award for service to
the profession.
Topping everything off, the Jefferson Doctor
of Midwifery Program graduated its first class
and inaugurated a major national symposium,
Midwifery Thinks!, which celebrates midwifery
scholarship and innovation, and
convenes midwifery leaders to
share strategies and create
coalitions to to promote
maternal health in the U.S.



Then, in May, Dr. Hackley was named a
Fellow of the American College of NurseMidwives (ACNM) and was given the ACNM’s
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PURSUING the POTENTIAL
for RNA BIOLOGY

RNA IS ESSENTIAL FOR THE PROCESS OF TURNING GENES' DNA
instructions into the proteins that actually drive
cellular functions. The field of RNA biology is
dynamic and growing, as researchers discover
the functions of a dizzying array of types of RNA.
Jefferson’s RNA biology program is multifaceted
and rich with potential for both understanding
human biology and developing ways to treat or
prevent disease.
For example, Ya-Ming Hou, PhD, professor of
biochemistry, guides a basic science research
program addressing RNA’s roles in a range of
biomedical challenges, from cancer to antibiotic
resistance. Recently, she may have identified an
RNA-based vulnerability in gram-negative bacteria
such as E.coli and Salmonella—which are antibioticresistant because their cells have two membranes
and numerous toxin pumps that expel antibiotic
molecules. Dr. Hou’s group has shown that creating
a defect in a specific transfer RNA (tRNA) undermines
those defenses. This finding holds promise as a
path for pursuing new, more effective antibiotics.
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tRNA molecules are not a typical antibiotic target;
they are part of the protein-building machinery cells
need to function. But Dr. Hou’s team found that to
function properly, bacteria require the addition of a
methyl group to one particular location on the spine
of several tRNAs. When these tRNAs were deficient
in methylation, the cells were more likely to have
protein-building defects. Next, Hou’s team created
bacteria genetically deficient in tRNA methylation,
and showed that the bacteria had more-permeable
membranes and were less effective at pumping out
chemicals, compared to normal bacteria. Finally,
when the bacteria with defective tRNAs were
exposed to antibiotics, they died faster and were less
capable of developing drug resistance. The team is
now screening molecules that could drive the same
de-methylation effect as the genetic engineering;
and, because the target in bacterial tRNAs is absent
from human cells, the resulting drug could be less
likely to have off-target effect on human cells.
Dr. Hou and colleague Davide Trotti, PhD, professor
of neuroscience, have also been studying the role
of specific tRNAs in neurodegenerative diseases
such as amyotrophic lateral sclerosis (ALS)—pursuing
investigations of a particular tRNA’s role in the
disease and whether it could be a therapeutic target.
In that context, Drs. Trotti and Hou have undertaken
an NIH-funded study on the most common cause
of inherited ALS: a mutation resulting in patients
having hundreds or even thousands copies of
GGGGCC sequence in the gene C9orf72.

Ya-Ming Hou, PhD
Professor of Biochemistry
Davide Trotti, PhD
Professor of Neuroscience

Recent work by Dr. Trotti’s group—in collaboration
with Aaron Haeusler, PhD, assistant professor of
neuroscience, and Piera Pasinelli, PhD, Frances
and Joseph Weinberg Professor of Neuroscience
and Director of the Jefferson Weinberg ALS
Center—looked at what triggers these repeated
sequences in the C9orf72 gene to eventually
produce the toxic proteins associated with ALS
(as well as with frontotemporal dementia and
other neurodegenerative diseases in patients
carrying the mutation). Suspecting that stressors
may be a trigger, the investigators tested a
number of agents that cause neurons to turn
on the stress responses. Indeed, many of these
also initiated production of toxic protein. The
investigations also showed that neuronal over-

excitation—similar to what happens during a
seizure—also triggered the protein production.
Once the integrated stress response is activated,
it is difficult to stop the production of the toxic
proteins. But, by honing in on this over-arching
cellular mechanism, the researchers gained insights
on specific methods that might block the neurondamaging response. The drug trazodone, which is
approved for the treatment of depression, is known
to act on parts of the integrated stress response.
The researchers tested it in their repeat-mutation
cellular model of the disease and found that it
could block toxic protein-production. Now, they
are screening for other molecules that might be
even more effective at blocking the process. 
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COMPUTATIONAL MEDICINE
CENTER UNCOVERS NEW
RNA CATEGORIES
THE INTERDISCIPLINARY EXPERTS OF JEFFERSON’S COMPUTATIONAL
Medicine Center combine high-performance
computing, data-driven hypothesis generation and
wet laboratory work to unravel the biology and role
of short RNA molecules with powerful regulatory
roles. The Center’s research is led by Isidore
Rigoutsos, PhD, Richard H. Hevner Professor of
Computational Medicine; Yohei Kirino, associate
professor of biochemistry and molecular biology;
and Eric Londin, PhD, assistant professor of
pathology, anatomy and cell biology.
The group has uncovered new RNA categories and
many previously unsuspected molecules that act as
regulators. They have also demonstrated that the
identity and abundance of these newly discovered
regulators depend on a person’s sex, population
origin and ethnicity—as well as on tissue type, tissue
state and disease.
For example, the team has shown that the size and
specific sequence of fragments of transfer RNA
(tRNA) depend on the kind of cancer cell in which
they are found: in their studies, the same parental

tRNA produced fragments that differed depending
on whether they were in, for example, breast cancer
or prostate cancer cells. When the researchers
analyzed broader data from a group of 32 cancers,
they found an array of complex relationships among
tRNA fragments, messenger RNA (mRNA), proteins,
genomic architecture, repetitive elements and the
mitochondrion. The work suggested that tRNA
fragments are as important as the full-length parental
molecules; that they have extensive interconnections
to gene templates and gene products that differ by
disease type; and that these interconnections can be
affected by a person’s sex. The findings could provide
new angles of attack specific to the type of disease
and the sex of the patient.
The investigators’ analysis further revealed that
all 32 cancer types harbor essentially the same
tRNA fragments and mRNA, but in very different
abundances. Moreover, the fragments and the
mRNA associate with each other in specific pairs
that differ in each cancer. Surprisingly, even though
the tRNA fragments partner with different mRNA
in each cancer, these mRNA belong to the same
core biological processes. The discovery suggests
more ways in which cancers might differ from one
another—and suggests that expression of the same
gene can go awry differently in different cancer
types. “These tRF-mRNA associations could provide
valuable insights for how to approach research into
treatment,” Rigoutsos notes, “because they capture
different relationships in every cancer.” 

BASIC// DISCOVERY

TREATING LUNG CANCER
with NANOPARTICLES
NON-SMALL CELL LUNG CANCER (NSCLC)—THE MOST COMMON
type of lung cancer—is very difficult to treat,
but Sunday Shoyele, PhD, associate professor
of pharmaceutical sciences, has developed
a nanotechnology-based treatment. The
new approach, which was effective in recent
tests with mouse models, uses nanoparticles
to deliver a molecule known to stall NSCLC
tumor growth and believed to make cancer
cells more susceptible to chemotherapy.
The molecule—microRNA 29b—is an example
of the category of “silencing RNAs” (siRNAs) that
interfere with the pathway by which individual
genes are expressed. siRNAs are capable of both
shutting down disease-causing processes in
the cell and stripping away diseased cells’ ability
to resist treatments. The challenge is getting
them intact to the point of disease. Dr. Shoyele’s
research program focuses on creating efficient and
effective ways to deliver these therapeutic tools.
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Sunday Shoyele, PhD
Associate Professor of
Pharmaceutical Sciences

In the case of microRNA 29b, the problem is that
the molecule quickly degrades in the bloodstream
or is removed by immune cells. Therefore, Dr.
Shoyele developed a special delivery mechanism.
It is a nanoparticle comprised of three active
parts: human immunoglobulin G, which cloaks
the particle from the immune system; an antigen
that seeks out lung tumors; and the therapeutic
payload, microRNA-29b. Those three elements
are bound together by a sticky polymer to form a
spherical nanoparticle.
In the mouse models, the nanoparticles succeeded
in reaching the tumors, which shrunk as a result. Dr.
Shoyele is now pursuing comprehensive toxicity tests
in animal models and is scaling up the nanoparticle
manufacturing process—preparing for the treatment
to enter clinical trials. 
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CLINICAL// TRANSLATIONAL

TREATING the MOST COMMON
LIVER DISORDER
NON-ALCOHOLIC LIVER DISEASE, ALSO KNOWN AS FATTY LIVER
Disease, is the most common liver disorder in
western nations. Up to 30 percent of Americans
have some level of the disease, and it will soon
be the country’s leading cause for liver transplant.
As its name suggests, Fatty Liver Disease begins
simply with storage of excess fat in the liver, but can
progress into serious liver inflammation and to the
extensive scarring of liver tissue known as cirrhosis.
Currently, biomedical researchers have a limited
understanding of what causes the disease and drives
its progression. Dina Halegoua-DeMarzio, MD,
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associate professor of medicine and director
of Jefferson’s Fatty Liver Center, and her
colleagues are working to uncover the cellular
mechanisms underlying the disease, in part by
identifying associated conditions. “Although
Fatty Liver patients are often overweight, suffer
insulin resistance and diabetes, and have high
cholesterol,” Dr. Halegoua-DeMarzio explains,
“we have found further associations with celiac
disease and binge-eating disorders, and are
investigating the exact relationships and causeand-effect connections among these conditions.”

There are no non-invasive methods of diagnosing
the emerging condition. That is why the Fatty Liver
Center is testing

new diagnostic methods

and conducting an array of clinical trials.

There is also much to be learned on the clinical
level: There are no non-invasive methods of
diagnosing the emerging condition—at present,
liver biopsies are necessary—and no medications
known to prevent or cure the disease. That is why
the Fatty Liver Center is testing new diagnostic
methods and conducting an array of clinical trials
of potential therapies. Among the most promising
drug studies are two phase III trials of treatments
for patients with moderate liver scarring, and two
phase II trials of therapies that show evidence of
reducing liver fat levels and removing cholesterols
that contribute to fat build-up in the liver. 

BASIC// DISCOVERY

MODELING the SYSTEMS of LIFE
Rajanikanth Vadigepalli, PhD, professor of
pathology, anatomy and cell biology, is a
chemical engineer and systems biologist who
views the body as a series of systems nested
within systems, interacting in dynamic ways.
He and his colleagues use high-powered
computers to create complex models of
how tissues and organs function, which they
compare to observations of in vitro and in vivo
lab models. The iterative process enables them
to find minute, molecular level effects with
outsized significance.
One of Dr. Vadigepalli’s primary research
focuses is the liver. He and his collaborators

analyze the organ at molecular, cellular and
tissue levels to learn how complex, causeeffect relationships trigger liver cells’ normal
regenerative activity (a surgically reduced
liver usually regrows in months)—and,
conversely, what happens when exposure
to excess alcohol or fats overcome cells’
regenerative capacity and the whole liver
begins to fail. Their work is changing some
long-held assumptions. For example,
alcoholic liver failure has long been viewed
as a process where the organ tolerates
alcohol for a period and then suddenly
decompensates at one catastrophic

inflection point. However, Dr. Vadigepalli has
found that alcoholic liver failure is actually a
progressive process: damage accumulates
over time as individual cells become more
sensitive to injury with each passing insult;
eventually, a tipping point is reached when
too many individual cells lose function
and the larger system—the liver—fails.
By helping to explain how systems actually
work, Dr. Vadigepalli is opening new paths for
diagnosing, treating and preventing an array of
serious diseases and for bringing regenerative
medicine ever closer to reality.
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A DISTINGUISHED
CAREER HONORED–
And the Work Continues

THE MOST PRESTIGIOUS AWARD IN INTERNATIONAL DERMATOLOGY—
the World Congress of Dermatology’s Alfred Marchionini
Medal in Gold—is bestowed every four years, and in 2019,
Jouni Uitto, MD, professor and chair of dermatology and
cutaneous biology, was the humble recipient. The award
is a recognition of Dr. Uitto’s long and distinguished
career, in which he has published nearly 900 peerreviewed articles, textbook chapters and reviews—
including 30 new publications over the past year.
Dr. Uitto is particularly renowned for his research
on a group of genetic diseases called epidermolysis
bullosa (EB), which manifest at birth with extensive
skin blistering and scarring. In its most severe form,
EB can be fatal during a child’s first weeks or months
of life. His lab discovered the disease’s genetic basis:
mutations in the collagen7A1 gene undercut the
production of a protein necessary for keeping layers
of the skin together. The lab then developed a
transgenic mouse model of EB, which became a
platform for development of treatment approaches.
Today, five gene therapy approaches in clinical trial
have their origins in Dr. Uitto’s work.
He is also driving advances on the rare childhood
disease pseudoxanthoma elasticum (PXE)—where
mineral build-up in elastic fibers of the skin and
blood vessels leads to formation of plaques in
blood vessels and eyes that cause heart attacks
and blindness. Collaborating closely with parents of
children with PXE, Dr. Uitto gathered DNA samples
that enabled his lab to identify the responsible genes.
Today, clinicians can make a prognosis based on
a patient’s specific set of mutations, and research
continues to develop and test effective therapies. 
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Jouni Uitto, PhD
Professor and Chair of Dermatology
and Cutaneous Biology
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SOLVING the PUZZLE
of FIBROTIC DISEASES
UP TO 40 PERCENT OF DISEASE MORTALITY IN DEVELOPED
countries results from fibrotic diseases, a family
of conditions where the build-up of scarlike tissue interferes with the body’s normal
function. These conditions can be systemic
(such as systemic sclerosis and scleroderma) or
affect individual organs such as the lung, liver,
kidney, heart or eye. Because the mechanisms
underlying these conditions are poorly understood
and treatments are few, Jefferson has made a
major commitment to basic and translational
research on a broad range of fibrotic diseases.
Pulmonary Fibrosis (PF) causes progressive,
potentially fatal scarring of the lung. PF results, in
part, from the inability of aging lung epithelial cells to
regenerate after injury. This may be because aging
cells do not direct nutrients to areas at greatest
need after injury. Ross Summer, MD, professor
of medicine, has been working to determine the
interconnections between cellular metabolism and
injury repair. His studies on young cells’ metabolic
adaptation to injury offer clues on how aging
compromises the repair process—and suggests
therapeutic approaches. For example, Dr. Summer
has found that blocking lipid synthesis, alone, can
cause fibrotic scarring in animal models; and, in
counterpoint, has demonstrated that increased
lipid production could reduce fibrosis-caused lung
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scarring significantly. He is now working to identify
and test molecules that could have therapeutic
effect by enhancing or protecting lipid synthesis.
Because scars that form in all injured tissues and
organs are comprised primarily of collagen-rich
fibrils, Andrzej Fertala, PhD, professor of orthopaedic
surgery, has been developing an antibody to block
an early step in fibril formation. Having shown the
antibody to be effective at blocking fibril production
in a mouse model of pulmonary fibrosis and a rabbit
model of arthrofibrosis, Dr. Fertala is now fine-tuning
it to create a therapeutic-grade biologic. Teaming
with orthopaedic surgeons, Dr. Fertala’s group is also
testing the possibility of employing the anti-fibrotic
antibody to block fibrosis of injured peripheral nerves,
which hampers the nerve regeneration process.
Cataract surgery often results in a fibrotic disease
known as Posterior Capsule Opacification (PCO),
which can lead to loss of vision. Sue Menko, PhD,
professor of pathology, anatomy and cell biology,
developed a chick embryo model of PCO and uses
it to identify cell-signaling pathways involved in
fibrosis and to study other mechanisms of wound
healing and fibrosis. These studies have led to
a series of significant discoveries. For example,
she and Janice Walker, PhD, assistant professor
of pathology, anatomy and cell biology, found

BASIC// DISCOVERY

Image from Sue Menko, PhD, and Janice
Walker, PhD: A 3D image of fibrotic cells
associated with the lens fibrotic disease
Posterior Capsule Opacification (PCO).

that the lens harbors a resident population of
vimentin-rich mesenchymal cells that migrate
to the wound edge, where they play a role in
wound repair. Spurred by their encounter with a
microenvironment of increased rigidly, these cells
differentiate to myofibroblasts—the principal cell
type associated with fibrosis. Subsequently, the
researchers found that injury spurs the release of
the protein vimentin, which binds to mesenchymal
cells at the wound and helps signal the shift
into a myofibroblast and the development of
fibrosis. These findings may provide novel targets
for development of new treatments for PCO.
Until very recently, the lens had been considered
not susceptible to the immune processes normally
associated with wound repair; most investigators
assumed that immune cells played no role in PCO.
However, using a lens-specific knockout mouse
model, Dr. Menko’s team found that degeneration
of the lens activates an immune response both
to the lens and throughout the eye (including
cornea, vitreous humor and retina) that contributes
to development of fibrosis associated with
cataractogenesis. Additionally, they demonstrated
that the lens is indirectly connected to the lymphatic
system, providing a potential mechanism for the
immune surveillance. Their findings have broad
implications for understanding disease and injuryrepair processes throughout the eye.
Children with a grave skin disorder known as
butterfly disease (epidermolysis bullosa or EB)
develop severe and chronic blisters and fibrosis
within their connective tissues. The condition
leads to club-like appendages where the skin
grows over the fingers or toes. Andrew South,
PhD, associate professor of dermatology and
cutaneous biology, has shown that fibrosis also
leads to an aggressive, often fatal, form of skin
cancer in butterfly children. Recently, Dr. South
and colleagues pinpointed how fibrosis develops
in butterfly children—and demonstrated that a
specific molecule interferes with the process and
reduces fibrosis in a tissue-engineered model. Now
his team is working to develop the molecule as a
potential therapy for the debilitating condition. 

THE JOAN & JOEL
ROSENBLOOM CENTER
for FIBROTIC DISEASES
Like cancer, fibrotic diseases are the result of complex
biological processes that are similar in their final
outcome, but diverse in the molecular mechanisms
underlying those processes. Thus, identifying treatment
targets and developing effective therapies is extremely
difficult. It requires a continuous dialogue between
basic scientists, translational researchers and clinical
investigators across a range of disciplines.
The Joan & Joel Rosenbloom Center for Fibrotic Diseases,
established in 2013, is an interdepartmental research
program focusing on diagnosis, disease mechanisms,
prevention and treatment of fibrotic diseases. It acts as a
bridge: both to translate basic findings into drug therapies
and to bring basic and clinical researchers together in
novel studies that often cross fields and diseases.
Joel Rosenbloom, MD, PhD, professor of dermatology
and cutaneous medicine, who directs the center,
is a globally respected biomedical scientist. Now in
his early 80s—with more than 50 years of research
and nearly 400 peer-reviewed scientific publications
under his belt—his active research program focuses
on pulmonary fibrosis and abdominal adhesions.
He and his wife, Joan, founded the Center with a
philanthropic gift soon after she was diagnosed with
inoperable lung cancer in 2012. He credits several
of his research breakthroughs to Joan, who worked
as his lab manager for many years (after her pursuit
of a PhD in physics was derailed by parenthood).
Today, he is frequently asked, “Why are you working
so hard? Why aren’t you retired?” Dr. Rosenbloom’s
response: “I think Joan would want me to be doing this.
These are cruel, terrible diseases, about which we know
too little to really help many patients. But by bringing
smart researchers together from many parts of the
institution—from cardiology, cancer biology, dermatology,
nephrology, ophthalmology, pulmonology, radiation
oncology and surgery—we are speeding progress in the
search for common pathways that would allow us to finally
understand and treat the full range of fibrotic diseases.”
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Jesse Roman, MD
Professor of Medicine
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EXPLORING the EPIGENETICS
of LUNG DISEASE
A recent study by Jesse Roman, MD, Ludwig Kind
Professor of Medicine, found that a mother’s diet
can prompt changes in how her offspring’s cells
function. It offers clear and specific evidence
that maternal experience can affect the health of
following generations: in this case, that insufficient
maternal nutrition during pregnancy can change
the functioning of genes that affect lung health.
In the study, researchers examined lung-related
genes in offspring of mice whose diet was limited
during the second and third trimesters of gestation.
They found that a handful of genes had a different

This research represents a

step forward in understanding
how follow-on generations' gene
function can be affected by maternal
or paternal experience.

level of expression in those progeny than did
the genes in offspring of mice who ate normally.
Two of those genes had particularly increased
expression; both help keep intact the lining of
blood vessels surrounding the lung’s alveoli and
promote their normal function. In addition, there
was also increased expression of a gene that may
predispose blood vessels to inflammation and
clotting. Finally, the researchers also found higher
levels of fibronectin—a connective tissue molecule
that normally helps cells organize into tissues, but
that sometimes attracts immune cells that prompt
excessive inflammatory reactions, like asthma.

Genetic mutations acquired by a mother
during her lifetime are not themselves passed
to subsequent generations. But changes in
epigenetics—cellular activities driven by molecular
processes not coded for in genes—can be passed
from parent to child. This research represents a
step forward in understanding how follow-on
generations’ gene function can be affected by
maternal or paternal experience.
A next step for Dr. Roman and his colleagues
is to explore in greater detail how altered gene
expression affects lung function. It is possible
that epigenetic changes in lung-specific genes—
such as Dr. Roman found in his groundbreaking
study—could be associated with the long-observed
phenomenon of higher rates of lung disease in
children born to undernourished mothers. 
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APPLIED//

FUNCTIONAL

FABRICS:
From Mining Oceans to Walking in Space

THOMAS JEFFERSON UNIVERSITY TRACES ITS ANCESTRY,
in part, to the 1884 founding of the Philadelphia
Textile School, the nation’s first center for textilefocused education. That institution continued
to be a pioneer in textile science, technology
and innovation for more than 130 years. Today,
that legacy is visible in an array of nationally and
globally recognized textile-related academic and
research programs—notably including research,
analysis and development of “functional fabrics”
that serve a broadening range of purposes.
Jefferson is one of the few academic institutions
possessing the full scope of expertise and technical
facilities needed to reduce fundamental ideas to
practice. As such, it fosters work ranging from
discovery research and technical analysis of new
materials, to design, prototype and development
of formed products. Leveraging cross-disciplinary
collaborations, faculty and students pursue basic
science investigations; translate and apply their
findings through ideation, prototyping and clinical
or industrial testing; and develop production and
supply-chain processes and marketing strategies.
The resulting concepts, methods and products
address the needs of a wide range of audiences,
from healthcare providers and patients, industrial
manufacturers and consumers, to United States
government agencies and world-class athletes.

50

THOMAS JE FFE RSON UNIVE RSIT Y // Jef ferson.edu/Research2020

Jefferson has roots in the 1884
founding of the Philadelphia Textile
School, the nation's first center for
textile-focused education.
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New Functional Fabrics and Garments
Since the 1970s, the University has produced highperformance material used to construct the gloves
that NASA astronauts use during spacewalks. More
recently, fashion design and engineering students
developed creative outer-layer designs for the “Z-2
Prototype” of NASA’s next-generation spacesuit.
In 2017, a student team won top prize in a United
States Department of Defense (DoD) challenge
to redesign protective chemical-biological suits
for U.S. warfighters. Their innovative concepts
for materials and construction—a synthesis of
original apparel design with the integration of new
technologies—promised to significantly enhance
comfort and improve tactility and dexterity during
military action. The team has since worked with
the DoD to bring their ideas and designs to reality.
Faculty and students have researched and
developed new functional fabrics and garments
for other kinds of high-intensity, high-stress
situations. One is Olympic rowing, for which
a team led by Mark Sunderland, MS, Robert J.
Reichlin High-Performance Apparel Chair, created
a seamless, single-piece uniform. Sunderland’s
group developed a new fabric and an innovative
whole-garment knitting process, and created a
uniform that fit like a virtual “second skin” for U.S.
rowers in the 2016 Olympic games. He and his
colleagues are now putting the finishing touches on
new uniforms for the U.S. skeleton team preparing
to compete in the 2022 winter games in Beijing.
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New Medical Treatments
Continuing research and development of purposespecific functional fabrics is also benefiting
people with chronic disease or serious injury.
Teams of clinicians, textile engineers and other
technical experts are working at various stages
of conceptualization, research and development
of products. These include a functional vest for
multiple sclerosis patients; fabric-based protective
head garments for people with major head injury;
polymer science-based fibers that hasten wound
closure and healing; and a range of materials
capable of sensing and transmitting clinically
relevant biochemical or physiological changes. In
the Edward P. Marram Biomedical Textile Structures
Laboratory, researchers are pairing advanced textile
structures with cultured stem cells to study the
functionality of cell-covered textiles for medical
use. One current project focuses on a potential
‘cardiac patch’ for treating coronary artery disease.

APPLIED//

Novel Purposes
But functional fabrics have uses beyond garments
and medical treatments. Marcia Weiss, MFA,
associate professor of textile design, specializes
in helping create new kinds of knitted and woven
fabrics with novel purposes or unusual qualities—
for example, fabric that conducts electricity in a
way that causes it to change shape when subject
to current. Weiss directs the state-of-the-art
Fashion and Textiles Futures Center (FTFC), which
focuses on textiles product design, engineering
and function analysis, and enables student/
faculty teams to partner with public and private
organizations on innovative real-world projects.

NEW SPACE and NEW
NAME for MATERIALS
TESTING LAB
Jefferson’s technical facilities for research,
development and testing of new fabrics may
be unsurpassed in higher education: Grundy
Materials Evaluation Laboratory has been
assessing new and newly combined materials
for more than 40 years. This year, it will have
a new name and a new home. Thanks to
the support of noted textile design alumnus
Jeff Bruner ’73, the Jeff Bruner Materials
Characterization Laboratory will open in the
state-of-the-art Kay and Harold Ronson Health
and Applied Science Center this spring.

“FTFC teams work on an extraordinary range
of projects,” explains Weiss. “We have designed
fabrics that respond to heat and ice, and created
novel products using completely new materials
created by industry.” For example, the Oak Ridge
National Laboratories asked the team to help
research and design a textile that would extract
heavy metals from the sea, and they created a
product that combined materials never before
integrated together. “NASA engaged us to develop
a fabric using carbon nanofibers, with layers as
parallel as possible and linear strength running
in one direction,” says Weiss. “We created a very
effective prototype, and they recently asked
us to develop the next phase of the fabric.”

The Lab’s main mission remains the same:

Brian George, PhD, associate professor of
engineering, is a textile engineer and materials
maker whose primary research focuses on
converting non-traditional materials into nonwoven
fabrics for a variety of uses. He and colleagues,
Diana R. Cundell, PhD, professor of biology, and
Alexander Messinger, MSArch, MArch, MCP,
professor emeritus, have developed new biocidal
textiles that naturally kill bacteria, mold and
fungi. Such materials have many potential uses,
including kitchen countertops and “breathing
wall” systems capable of killing bacteria in hospital
rooms and physicians’ offices. On a different
track, Dr. George is investigating uses of waste
fibers from manufacturing hats and other feltbased products. His purpose here is to explore
the fibers’ potential for increasing the strength
of concrete and other building composites and
for enhancing soil fertility for agriculture. 

potential military garments—notably, to evaluate
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to offer experiential learning, introducing
students to technology and processes for
evaluating materials. It has also been a
problem-solving workhorse for industry
and government agencies, with the capacity
to assess myriad factors, including friction,
wicking, strength, weight, high-compression
capacity and abrasion/snagging resistance.
“One of our more complex studies was the
seven-years-long War Fighters’ Apparel project,”
explains Janet Brady, MS, associate professor
of materials technology and the Lab’s faculty
director. “To perform full functional testing of
comfort and material strength and durability—
we formed multidisciplinary teams, including
computational analysts, computational chemists,
psychologists and human-factor specialists,
textile engineers and garment-development
experts. DoD adopted many of the garmentdesign details that we recommended.”
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REDUCING IMPLANTABLE
DEVICE INFECTIONS

Surgical site infections can be devastating to
patients; consequences can include sepsis, limb
loss and even death. In addition, these infections
can be costly to our nation’s healthcare system,
adding an average of 4.3 days to hospital stays
and $10,497 per patient to the overall cost.
“Although overall infection rates are very low—
currently, only about one percent of recipients
develop a CIED-related infection—they are bad
experiences for patients, potentially even fatal,”
says Dr. Greenspon.
EVEN AS JEFFERSON RESEARCHERS HELP ADVANCE MEDICAL
care by developing wholly new treatments,
methods and tools, they are also working hard to
reduce complications associated with procedures
performed by tertiary care centers across the country.
Post-procedure infections, in particular, can be a
pernicious and costly problem. Clinician-scientists
throughout the Jefferson system are pursuing clinical
trials that aim to address the problem.
For example, Arnold J. Greenspon, MD, professor
of medicine and director of the Jefferson Cardiac
Electrophysiology Laboratory, is working to
address the problem of infections associated with
cardiac implantable electronic devices (CIEDs),
such as pacemakers, implantable cardioverterdefibrillators and cardiac resynchronization therapy
devices. While any medical device or product
implanted in the human body can become infected,
hospitals across the country have seen the rate
of CIED infection grow faster than that of other
types of device implantations. These patients must
return to the hospital to have the device removed
and to undergo antibiotic treatment. Subsequently,
they must have a replacement implanted.
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Moreover, a study he co-authored last year
found that CIED infections are quite costly—
with expenditures for Medicare fee-for-service
beneficiaries ranging from $22,000 to $77,000
per case.

Studies to Prevent CIED Infections
For those reasons, Dr. Greenspon has been
collaborating in a series of research studies
seeking to define the factors that cause these
infections to develop. He has also partnered
in an array of multi-center trial approaches for
reducing the rate of CIED infection. A report on
the most recent of those trials, centering on an
absorbable, antibiotic-eluting mesh “envelope” for
the CIED, was published recently in New England
Journal of Medicine. It showed that use of the
antibacterial envelope resulted in a significantly
lower incidence of major CIED infections than
standard-of-care infection-prevention strategies
alone, without notable added complications.
Now, Dr. Greenspon is collaborating with
researchers at Vanderbilt University on a trial with

patients at high-risk for CIED infection. It will seek
to determine if use of the antibacterial envelope
with an additional, post-procedure application of
systemic antibiotics will further reduce incidence
of infection.

Compared to patients receiving standard
dressing, the negative pressure therapy resulted in
significantly fewer wound infections (9 percent),
reduced patient reoperation and readmission
and an average savings of $6,045 per patient.

Reducing Infections in Vascular Procedures

The second study, now in progress, is testing
negative pressure therapy for surgical wounds
following lower-leg amputation. Wound
complications in this setting have been reported
as high as 34 percent nationwide. This multicenter trial aims to enroll 440 patients who will
undergo above- or below-knee amputations
at one of six participating medical centers in
the United States and Europe. Results from the
study are expected to be available in late 2021.

Paul DiMuzio, MD, MBA, William M. Measey
Professor of Surgery and director of Jefferson’s
Division of Vascular and Endovascular Surgery,
has led two studies on the use of a “negative
pressure therapy” to reduce infections at the
incision site in vascular surgical procedures. Both
studies compare standard surgical dressings with
the PREVENA™ Dressing Kit, a negative pressure
dressing that continuously drains exudates from
surgical incisions, which is applied immediately in
the operating room.
The first study, published last year in the Journal
of Vascular Surgery, focused on vascular groin
incisions, where complications rates are as
high as 44 percent, nationally. The randomized
controlled trial focused on 119 femoral artery
incisions considered high-risk for complications.

“We are particularly excited about the potential
for reducing wound infections for this patient
population, many of whom are suffering from
peripheral vascular disease, diabetes or heart
failure and are particularly vulnerable to postsurgical infections," says Dr. DiMuzio. 

CLINICAL// TRANSLATIONAL

SIGNS of HUMANITY
People who use signs to ask for help
(“panhandle”) are a very visible fraction of a
city’s underserved or homeless population.
Yet, they are rarely heard. The signs they
carry are artifacts of this phenomena, but
they do not tell the complete story.
The Signs of Humanity Project was a
researcher-artist collaboration that explored
the interactions between people who are
“panhandling” and those who pass by.
The Project’s research arm qualitatively
explored the experiences of people who
panhandle; and its artistic arm created an
exhibit intended to mitigate this community’s
dehumanization. In July 2018, artist Willie
Baronet worked with Rosie Frasso, PhD,
CPH, public health program director, and a
team of MPH and MD students to begin data

collection and artifact acquisition. Baronet
purchased more than 100 signs from their
owners—paying on average $10 for each
and offering materials with which to make a
new sign. Those who sold their signs were
then asked to participate in a brief interview
where open-ended questions explored their
interactions with passersby, their opinions
about how money collected is used by other
people who panhandle and their perceptions
of how the opioid crisis has affected them.
In September 2018, Baronet curated an
exhibit of the signs purchased on the streets
of Philadelphia. In addition, during a special
public program at the exhibit, Dr. Frasso and
the student team presented their preliminary
research findings. Key among those findings
was the fact that the great majority of interview

respondents reported feeling invisible and
isolated, and noted that the opioid crisis
exacerbated their sense of isolation. On
the other hand, they reported feeling both
comfortable and pleased that their signs
would be used in an exhibit designed to
get people talking about homelessness.
Baronet also gained a novel perspective
from the project—that of a researcher. He
observed that, “It was cool to be working
with students who are so analytical and
research driven and had a huge level
of compassion and empathy.”
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POWERING RESEARCH on
MITOCHONDRIAL DISEASE
MITOCHONDRIA ARE SPECIALIZED STRUCTURES THAT EXIST
in all cells except red blood cells. Generally
known as the cell’s energy factory, mitochondria
play a much broader role: from helping in the
processes of making hemoglobin, detoxifying
ammonia in the liver, metabolizing cholesterol and
neurotransmitters and synthesizing estrogen and
testosterone. Each year, thousands of children (and,
increasingly, adults) are diagnosed with genetic
mitochondrial conditions that range from skeletal
muscle weakness and exercise intolerance to
neurodegenerative diseases, heart disease and liver
failure. In addition, mitochondria are increasingly
recognized as playing a role in the pathology of
diseases such as diabetes and cancer.

Mitochondria are known as the cell's
energy factory. They exist in all cells
except red blood cells.

Jefferson’s Center for Mitochondrial Imaging
Research and Diagnostics—known as the MitoCare
Center—investigates mitochondrial energetics,
signaling and dynamics to learn how changes in
mitochondrial biology cause disease and to identify
potential targets for new treatments. Fundamental
to MitoCare Center researchers’ work is advanced
microscopy that—combined with cutting-edge
metabolic technologies, genetics and proteomics—
enables them to observe mitochondria functioning
in both normal and diseased tissues. These
capacities also enable Center investigators to
create better methods of diagnosing mitochondrial
diseases and testing potential therapies.
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MitoCare comprises five core research teams, plus
an array of associated multidisciplinary teams whose
research crosses into mitochondrial biology. The
team led by MitoCare director Gyorgy Hajnoczky,
MD, PhD, the Raphael Rubin, MD, Professor of
Pathology, Anatomy and Cell Biology, was among
the first to visualize mitochondrial energy metabolism
and ion transport in single live cells. This work helped
to elucidate fundamental signaling mechanisms that
coordinate mitochondrial action with broader cellular
function. His team has also been developing live cell
imaging capacity that allows bioscientists from many
disciplines to study intracellular processes.
MitoCare researchers are also applying the Center’s
technical capacities to study mitochondria’s precise
role in specific diseases. For example, Erin Seifert,
PhD, associate professor of pathology, anatomy
and cell biology, is pursuing two NIH-funded
studies on the multifaceted role skeletal-muscle cell
mitochondria play in the development of disease—
including an investigation of how malfunctioning
muscle mitochondria can undermine glucose
regulation throughout the body, leading to type
2 diabetes. Shey-Shing Sheu, PhD, professor of
medicine, and Gyorgy Csordas, MD, associate
professor of pathology, anatomy and cell biology, are
working to define the central role that mitochondria
play in the development of ischemic heart disease,
cardiac arrhythmias, cardiomyopathy and heart
failure. And Dmitry Temiakov, PhD, associate
professor of biochemistry and molecular biology,
studies how the process of DNA transcription and
replication in mitochondria differs in normal versus
cancer cells. 
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8,100+ students
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organizations ranging from the National Institutes
of Health (NIH), the US Department of Defense
and the Pennsylvania Department of Health
to the Nancy Laurie Marks Foundation to the
Genentech, Merck and Celgene corporations

1,000+ patents for new drugs, software
innovations, medical devices and diagnostic tools
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across 10 colleges and 4 schools
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LOOKING AHEAD: NEW BIOMEDICAL
RESEARCH BUILDING PLANNED for
CENTER CITY CAMPUS
Thomas Jefferson University received a $70
million gift from Sidney and Caroline Kimmel to
advance research at the University. The gift will
support the new Caroline Kimmel Biomedical
Research Building, which will be a home for big
ideas and will provide Jefferson scientists with
leading-edge technology and laboratories. The
new facility will markedly expand Jefferson’s
research capacity and create a “research corridor”
that facilitates connections and collaborations
among researchers across the University. 

Learn how to support more discoveries that
improve lives: Jefferson.edu/GiveResearch
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